Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 1A PHASE 1, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY 
AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE 
FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE
Study Intervention Number:
Study Intervention Name: N/A
US IND Number: TBD
EudraCT/CTIS Number: N/A
ClinicalTrials.gov ID: TBD
Pediatric Investigational Plan Number: N/A
Protocol Number: C4801001
Phase: Phase 1
Brief Title: A Phase 1 Study to Evaluate the Safety and Immunogenicity of Pne umococcal 
Conjugate Formulations in Healthy Adults 18 Through 49 Years of  Age 
 
 
 
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 26 May 2022PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................. ............................................................... .....8
1. PROTOCOL SUMMARY............................................ .........................................................9
1.1. Synopsis .................................................. ............................................................... ...9
1.2. Schema .................................................... ............................................................... .17
1.3. Schedule of Activities .................................... .........................................................18
2. INTRODUCTION ................................................ ............................................................... 21
2.1. Study R ationale ........................................... ............................................................21
2.2. Background ................................................ .............................................................21
2.3. Benefit/Risk Assessment.................................... .....................................................23
2.3.1. Risk Assessment ......................................... ................................................25
2.3.2. Benefit Assessment...................................... ...............................................27
2.3.3. Overall Benefit/Risk Conclusion......................... .......................................27
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS ........................ ...................................27
4. STUDY DESIGN................................................ ............................................................... ..28
4.1. Overall Design............................................ .............................................................28
4.2. Scientific Rationale for Study Design..................... ................................................30
4.2.1. Diversity of St udy Population ........................... .........................................31
4.2.2. Choice of Contraception/Barrier Requirements ............ .............................32
4.3. Justification for Dose .................................... ..........................................................32
4.4. End of Study Definition ................................... .......................................................32
5. STUDY POPULATION ............................................ ..........................................................32
5.1. Inclusion Criteria........................................ .............................................................33
5.2. Exclusion Criteria........................................ ............................................................34
5.3. Lifestyle Cons iderations.................................. ........................................................35
5.3.1. Contraception........................................... ...................................................35
5.4. Screen Failures ........................................... .............................................................36
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention .. .........................36
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY ............... ..................36
6.1. Study Intervention(s) Administered ........................ ................................................38PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 46.1.1. Administration .......................................... ..................................................40
6.1.2. Medical Devices .......................................... ...............................................40
6.2. Preparation, Handling, Storage, and Accountability........ .......................................40
6.2.1. Preparation and Dispensing .............................. ..........................................42
6.3. Assignment to Study Intervention.......................... .................................................42
6.4. Blinding.................................................. ............................................................... ..42
6.4.1. Blinding of Participants ................................ ..............................................42
6.4.2. Blinding of Site Personnel.............................. ............................................42
6.4.3. Blinding of the Sponsor................................. .............................................43
6.5. Study Intervention Compliance............................. ..................................................43
6.6. Dose Modification......................................... ..........................................................43
6.7. Continued Access to Study Intervention After the End of th e Study......................43
6.8. Treatment of Overdose..................................... .......................................................43
6.9. Prior and Concomitant Therapy ............................. .................................................44
6.9.1. Prohibited During the Study ............................. ..........................................44
6.9.2. Permitted During the Study .............................. ..........................................44
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL..................................... ......................................44
7.1. Discontinuation of Study Intervention ..................... ...............................................44
7.2. Participant Discontinuation/Withdrawal From the Study ..... ..................................45
7.2.1. Withdrawal of Consent................................... ............................................45
7.3. Lost to Follow-Up ......................................... ..........................................................46
8. STUDY ASSESSMENTS AND PROCEDURES............................. ..................................46
8.1. Administrative Procedures ................................. .....................................................46
8.2. Efficacy and/or Immunogenicity Assessments ................ .......................................47
8.2.1. Biological Samples ...................................... ...............................................48
8.3. Safety Assessments ........................................ .........................................................48
8.3.1. Participant Electronic Diary ............................ ...........................................49
8.3.2. Grading Scale for Prompted Events ....................... ....................................49
8.3.2.1. Local Reactions ....................................... ..................................49
8.3.2.2. Systemic Events ....................................... .................................50
8.3.3. Physical Examinations................................... .............................................52PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 58.3.4. Vital Signs ............................................. .....................................................52
8.3.5. Clinical Safety Laboratory Assessments .................. ..................................52
8.3.6. Pregnancy Testing ....................................... ...............................................52
8.4. Adverse Events, Serious Adverse Events, and Other Safety R eporting .................53
8.4.1. Time Period and Frequency for Collecting AE and SAE Info rmation.......53
8.4.1.1. Reporting SAEs to Pfizer Safety....................... ........................54
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF.......... .........54
8.4.2. Method of Detecting AEs and SAEs ........................ ..................................54
8.4.3. Follow-Up of AEs and SAEs............................... .......................................54
8.4.4. Regulatory Reporting Requirements for SAEs.............. .............................55
8.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure ....................... ..............................55
8.4.5.1. Exposure During Pregnancy............................. .........................55
8.4.5.2. Exposure During Breastfeeding ......................... .......................57
8.4.5.3. Occupational Exposure ................................. ............................57
8.4.6. Cardiovascular and Death Events......................... ......................................58
8.4.7. Disease-Related Events and/or Disease-Related Outcomes N ot 
Qualifying as AEs or SAEs...................................... ........................................58
8.4.8. Adverse Events of Special Interest...................... .......................................58
8.4.8.1. Lack of Efficacy...................................... ..................................58
8.4.9. Medical Device Deficiencies............................. .........................................58
8.4.9.1. Time Period for Detecting Medical Device Deficiencies . ........58
8.4.9.2. Follow-Up of Medical Device Deficiencies.............. ................59
8.4.9.3. Prompt Reporting of Device Deficiencies to the Sponsor ........59
8.4.9.4. Regulatory Reporting Requirements for Device 
Deficiencies ................................................... ....................................59
8.4.10. Vaccination Errors..................................... ...............................................59
8.5. Pharmacokinetics .......................................... ..........................................................60
8.6. Genetics.................................................. ............................................................... ..61
8.6.1. Specified Genetics ...................................... ................................................61
8.6.2. Retained Research Samples for Genetics .................. .................................61
8.7. Biomarkers ................................................ ..............................................................6 1PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 68.8. Immunogenicity Assessments ................................ .................................................61
8.9. Health Economics .......................................... .........................................................61
8.10. Study Procedures......................................... ..........................................................61
8.10.1. Visit 1 – Study Intervention Administration – Day 1...... .........................61
8.10.2. Visit 2 – Follow-Up After Study Intervention Administrat ion – 28 
to 42 Days After Study Intervention Administration............. ..........................64
8.10.3. Unscheduled Visit for a Grade 3 Systemic Event or Suspe cted 
Grade 4 Reaction............................................... ...............................................64
9. STATISTICAL C ONSIDERATIONS .................................. ..............................................65
9.1. Statistical Hypothesis .................................... ..........................................................66
9.1.1. Estimands............................................... .....................................................66
9.2. Analysis Sets ............................................. ..............................................................6 6
9.3. Statistical Analyses ...................................... ...........................................................67
9.3.1. General Considerations.................................. .............................................67
9.3.1.1. Analyses for Binary Data .............................. ............................67
9.3.1.2. Analyses for Continuous Data.......................... .........................67
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis ................ ................................68
9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis .............. ..............................68
9.4. Interim Analyses .......................................... ...........................................................69
9.4.1. Analysis Timing......................................... .................................................69
9.5. Sample Size Determination................................. ....................................................69
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ................................................. .........................................................71
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Cons iderations ...............71
10.1.1. Regulatory and Ethical Considerations .................... ................................71
10.1.1.1. Reporting of Safety Issues and Serious Breaches of th e 
Protocol or ICH GCP............................................ .............................71
10.1.2. Financial Disclosure ................................... ..............................................72
10.1.3. Informed Consent Process ............................... .........................................72
10.1.4. Data Protection ........................................ .................................................73
10.1.5. Committees Structure ................................... ............................................73
10.1.5.1. Data Monitoring Committee ............................. ......................73PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 710.1.6. Dissemination of Clinical Study Data ................... ...................................73
10.1.7. Data Quality Assurance ................................. ...........................................75
10.1.8. Source Documents....................................... .............................................76
10.1.9. Study and Site Start and Closure ....................... .......................................76
10.1.10. Publication Policy.................................... ...............................................77
10.1.11. Sponsor’s Medically Qualified Individual.............. ................................78
10.2. Appendix 2: Clinical Laboratory Tests ...................... ...........................................79
10.3. Appendix 3: Adverse Events: Definitions and Procedures fo r Recording, 
Evaluating, Follow-Up, and Reporting ........................... ..........................................80
10.3.1. Definition of AE ....................................... ................................................80
10.3.2. Definition of an SAE ................................... .............................................81
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs Du ring 
the Active Collection Period................................... .........................................83
10.3.4. Reporting of SAEs...................................... ..............................................86
10.4. Appendix 4: Contraceptive and Barrier Guidance ........... .....................................88
10.4.1. Male Participant Reproductive Inclusion Criteria ....... .............................88
10.4.2. Female Participant Reproductive Inclusion Criteria..... ............................88
10.4.3. Woman of Childbearing Potential ........................ ....................................89
10.4.4. Contraception Methods.................................. ...........................................90
10.5. Appendix 5: Genetics ..................................... .......................................................92
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up  Assessments .......93
10.7. Appendix 7: Kidney Safety Monitoring Guidelines .......... ...................................95
10.7.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury ..................................... .........................................95
10.7.2. Age-Specific Kidney Function Calculation Recommendation s...............95
10.7.2.1. Adults (18 Years and Above)—2021 CKD-EPI 
Equations ...................................................... .....................................95
10.7.3. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities.................................................. .................................................95
10.8. Appendix 8: AEs, ADEs, SAEs, SADEs, USADEs, and Device 
Deficiencies: Definitions and Procedures for Recording, Evaluat ing, 
Follow-Up, and Reporting in Medical Device Studies ............. ................................96
10.8.1. Definition of AE and ADE ............................... ........................................96
10.8.2. Definition of SAE, SADE, and USADE ..................... .............................96PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 810.8.3. Definition of Device Deficiency........................ .......................................97
10.8.4. Recording/Reporting and Follow-Up of Medical Device 
Deficiencies................................................... ...................................................97
10.8.5. Reporting of SAEs...................................... ..............................................99
10.8.6. Reporting of SADEs..................................... ............................................99
10.9. Appendix 9: Abbreviations ................................ .................................................100
11. REFERENCES ................................................. ............................................................... 103
LIST OF TABLES
Table 1. Study Intervention Groups............................... .........................................29
Table 2. Grading Scales for Local Reactions ...................... ...................................50
Table 3. Grading Scales for Systemic Events...................... ...................................51
Table 4. Ranges for Fever........................................ ...............................................52
Table 5. Probability of Detecting at Least 1 Adverse Event in a S tudy Group ......70PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY 
1.1. SynopsisProtocol Title: A Phase 1, Randomized, Open-Label Trial to Evaluate the Safety a nd 
Immunogenicity of Pneumococcal Conjugate Formulations in Health y Adults 18 Through 
49 Years of Age
Brief Title: A Phase 1 Study to Evaluate the Safety and Immunogenicity of Pn eumococcal 
Conjugate Formulations in Healthy Adults 18 Through 49 Years of  Age
Regulatory Agency Identification Number(s):
US IND Number: TBD
[EudraCT/CTIS] Number: N/A
ClinicalTrials.gov ID: TBD
Pediatric Investigational Plan Number: N/A
Protocol Number: C4801001
Phase: Phase 1
Rationale:
Streptococcus pneumoniae causes invasive (eg, meningitis, sepsis, bacteremic pneumonia) 
and noninvasive (eg, OM, nonbacteremic pneumonia, sinusitis) di sease associated with 
significant healthcare burden, morbidity, and mortality. 13vPnC (Prevnar 13®) was licensed
by the FDA and other countries for use in infants and young chi ldren for the prevention of 
pneumococcal disease more than a decade ago. It was subsequentl y indicated for prevention 
of pneumonia in adults ≥18 years of age. 13vPnC has been introd uced into national 
immunization programs for pediatric and adult populations aroun d the world. 20vPnC was 
developed to expand protection against pneumococcal invasive dis ease and pneumonia and 
has been approved by the FDA and EMA for adults ≥18 years of ag e. 20vPnC contains the 
identical polysaccharide conjugates and excipients as 13vPnC bu t with additional conjugate 
polysaccharides for 7 additional serotypes.
 
 
 
 PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 10 
This randomized, open-label Phase 1 study is designed to evalua te the safety and 
immunogenicity of
 
Objectives, Endpoints, and Estimands:
Objectives Endpoints Estimands
Primary: Primary: Primary:
To describe the safety profile of 
candidates in adults 
18 through 49 years of age•Prompted local reactions 
(redness, swelling, and pain at the injection site)
•Prompted systemic events 
(fever, headache, fatigue, muscle pain, and joint pain)
•AEs
•SAEsIn participants receiving the study 
intervention from each group, the percentage of participantsreporting:
•Prompted local reactions 
within 7 days after administration
•Prompted systemic events 
within 7 days after 
administration
•AEs within 1 month after 
administration
•SAEs within 1 month after 
administration
Secondary: Secondary: Secondary:
To describe the immune responses elicited by the candidates•OPA titers In participants complying with the 
key protocol criteria (evaluable participants) from each group:
•  OPA GMTs 
1 month after administration
Overall Design:
This is a Phase 1, multicenter, randomized, open-label study to ev aluate alternative
 This study will be 
conducted at investigator sites in the US. Approximately 405 adul ts 18 t hrough 49 years of 
age with no history of pneumococcal vaccination will be enrolle d. Participants will be 
enrolled and randomized equally to 1 of 9 groups (45 participant s per group): 6 groups will 
receive 1 of 6 different candidates and 3 groups will receive eit her , 
13vPnC, or PCV15 (see Study Intervention Groups table below).PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 11There are 3 preformulated products that will be administered at 2  different volumes to create 
the 6 different candidates  
 
 
 
All formulations include AlPO 4.
The key control group will receive polysaccharide conjugate  
 contained in 13vPnC (Prevnar 13) and 20vPnC (Prevnar 20™). In addition, 
PCV15 (Vaxneuvance [Merck]) and 13vPnC are both licensed in the  US for use in adults and
will be included as supplemental controls.
Study Intervention Groups
GroupCarrier 
Protein ChemistryPolysaccharide 
Dose Dose Volume n
45
45
45
45
45
45
45PPD
PPD
PPD
PPD
PPD
PPDPPDPPD PPD
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 12Study Intervention Groups
GroupCarrier 
Protein ChemistryPolysaccharide 
Dose Dose Volume n
PCV15 (control) N/A N/A 0.5 mL 45
13vPnC (control) CRM 197 RAC 0.5 mL 45
Abbreviations: N/A = not applicable; RAC = reductive amination chemistry;  
On Day 1 (Visit 1), participants will be assessed for eligibili ty, have blood drawn for 
immunogenicity assessments, receive a dose of 1 of the candidates or controls, be 
observed for 30 minutes after administration, and receive safety  follow-up and e-diary 
instructions. The study interventions will be prepared and admini stered by designated staff.
Local reactions (pain, redness, and swelling) occurring at the injection site and systemic 
events (fever, fatigue, headache, muscle pain, and joint pain) will be prompted for and 
collected daily in an e-diary from Day 1 through Day 7 after admin istration of study 
intervention, where Day 1 is the day of administration. AEs (in cluding nonserious AEs and 
SAEs) will be assessed for approximately 1 month after study in tervention administration 
(through Visit 2).
At Visit 2 (28-42 days after Visit 1), participants will return  for follow-up. Information will 
be collected from the participants on AEs and e-diary follow-up (as needed), and blood will 
be drawn for immunogenicity assessments.
Approximately 15 participants from each group will be enrolled at specialty sites that will 
collect  
and approximately 20 mL for sera for OPA and IgG measurements. The remaining 
participants enrolled at other sites will have 60 mL of blood d rawn for sera for OPA and IgG 
measurements.
Number of Participants:
Approximately 405 participants (approximately 45 per group) will be randomized to study 
intervention.
Study Population:
Key inclusion and exclusion criteria are listed below (for the fu ll set of criteria, 
seeSection 5.1 and Section 5.2 of this protocol):PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 13Inclusion Criteria
Participants must meet the following key inclusion criteria to be eligible for enrollment into 
the study:
1. Male or female participants ≥18 and ≤49 years of age at the time  of consent.
2. Adults determined by clinical assessment (including medical h istory and clinical 
judgment) to be eligible for the study, including adults with pr eexisting stable disease 
(defined as disease not requiring significant change in therapy  or hospitalization for 
worsening disease) within 12 weeks before receipt of study inter vention.
3. Female participants of childbearing potential or male partici pants who are able to 
father children and are willing to use acceptable methods of co ntraception for at least 
28 days after the dose of study intervention; or female partici pants not of childbearing 
potential; or male participants not able to father children.
Note: Female participants of nonchildbearing potential must mee t the criteria 
described in the WOCBP section of the protocol.
4. Capable of giving signed informed consent, which includes com pliance with the
requirements and restrictions listed in the ICD and in this pro tocol.
Exclusion Criteria Participants with any of the following characteristics/condition s will be excluded:
1. History of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaphylaxis) to any component in pneumococcal con jugate vaccines and 
any other diphtheria toxoid–containing vaccine.
2. Serious chronic disorder, including metastatic malignancy, se vere COPD requiring 
supplemental oxygen, end-stage renal disease with or without di alysis, cirrhosis of the 
liver, clinically unstable cardiac disease, or any other disord er that in the 
investigator’s opinion would make the participant inappropriate  for entry into the 
study.
3. Other medical or psychiatric condition including recent (with in the past year) or 
active suicidal ideation/behavior or laboratory abnormality tha t may increase the risk 
of study participation or, in the investigator’s judgment, make  the participant 
inappropriate for the study.
4. Known or suspected immunodeficiency or other conditions assoc iated with 
immunosuppression, including, but not limited to, immunoglobuli n class/subclass 
deficiencies, generalized malignancy, HIV infection, leukemia, lymphoma, or organ 
or bone marrow transplant.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 145. Congenital, functional, or surgical asplenia.
6. Current febrile illness (body temperature ≥100.4°F [≥38.0°C])  or other acute illness 
within 48 hours before study intervention administration.
7. Previous vaccination with any licensed or investigational pne umococcal vaccine, or 
planned receipt of any licensed or investigational pneumococcal  vaccine through 
study participation.
8. Currently receives treatment with immunosuppressive therapy, including cytotoxic 
agents or systemic corticosteroids, or planned receipt through t he last blood draw 
(Visit 2). Participants may not be enrolled if corticosteroids were administered within 
28 days before study intervention administration. Inhaled/nebul ized, intra-articular, 
intrabursal, or topical (skin, eyes, or ears) corticosteroids ar e permitted.
9. Receipt of blood/plasma products or immunoglobulin within the  60 days before study 
intervention administration, or planned receipt during study pa rticipation.
10. Receipt of any inactivated or otherwise nonlive vaccine with in 14 days or any live 
vaccine within 28 days before administration of study intervent ion.
11. Participation in other studies involving investigational dru gs, investigational vaccines 
(except for investigational pandemic vaccines recommended and authorized in this 
population for emergency use ), or investigational devices within 28 days prior to 
study entry and/or during study participation. Participation in  purely observational 
studies is acceptable.
Study Arms and Duration:Each participant will participate in the study for approximatel y 1 month (Visit 1 through 
Visit 2). The study duration is estimated to be approximately 2 m onths.
 
 of the controls , 13vPnC 
and PCV15) will be administered intramuscularly in the deltoid m uscle of the preferably
nondominant arm by a site staff member or designee. The preformu lated products and 
controls will be provided to the site by the sponsor.PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 15Study Intervention(s)
Intervention 
Name(Formulations) 
  
  
  
 
 
 
 13vPnC 
(Prevnar 13)0.5 mL suspension for 
injectionVaxneuvance
(pneumococcal 15-valent conjugate 
vaccine)
suspension for injection
Arm name(group of participants receiving a 
specific 
intervention orno intervention)     
  
 
 13vPnC control 
groupPCV15 control 
group
Dose volume        0 . 5 m L
administered0.5 mL
administered
Route of administrationIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injection
Use Experimental Experimental Experimental Experimental Experimental Exp erimental Control Control Control
IMP or 
NIMP/AxMPIMP IMP IMP IMP IMP IMP IMP NIMP NIMPPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 16Statistical Methods:
The study size of this Phase 1 study is not based on any formal  hypothesis test for safety or 
immunogenicity results. All statistical analyses will be descri ptive.
The primary objective is to describe the safety profile of the  candidates; this will be 
done by summary statistics (including counts and percentages of  participants and the 
associated 2-sided 95% CIs) for local reactions, systemic event s, AEs, and SAEs for each 
study intervention group. With 45 participants per study group,  the study will provide a 
greater than 90% chance of observing at least 1 AE in each grou p if the true rate is at 
least 5%.
The secondary objective will be to describe the pneumococcal im munogenicity of the  
candidates by summarizing OPA GMTs approximately 1 month after study intervention 
administration for each group. The corresponding 95% CI for the GMTs will also be 
provided.
Ethical Considerations:Participants enrolled in this study are in an age group that is not currently covered by the 
indication for vaccines containing  conjugate. These participant s are relatively 
healthy and therefore are not recommended for pneumococcal conj ugate vaccines. Receiving 
the candidates or controls will not interfere with the standard  of care for these 
participants. For those with risk factors for pneumococcal vacc ination, the investigator site 
and ICD will inform participants to seek advice from their heal thcare provider regarding the 
need for immunization after the study.
The study will provide the immune impact of  
 
that could potentially benefit adults and children.
The investigational candidates have not yet been evaluated in cl inical studies; 
therefore, the initial safety data will be generated in this Ph ase 1 study.  
 
 
 
The most common AEs noted in adults after vaccination with 20vP nC 
are primarily related to local reactions (injection site pain, redness, and swelling) and 
systemic events (fever, headache, fatigue, joint pain, and musc le pain). Safety reviews of data 
from the 3 completed Phase 3 adult trials has not revealed any unexpected safety concerns.PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 17
PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 181.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and pr ocedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each proced ure and assessment required for compliance with the 
protocol.
The investigator may schedule visits (unplanned visits) in addi tion to those listed in the SoA table, in order to conduct evalu ations or 
assessments required to protect the well-being of the participa nt.
Visit Identifier Visit 1 Visit 2
Notes Visit Description Study Intervention 
AdministrationFollow-Up After Study Intervention 
Administration
Visit Window (Days) Day 128 to 42 Days After IP 
Administration • See Section 8.4.3 for follow- upAE and SAE assessments.
Obtain informed consent X •Informed consent should be obtained prior to undergoing any 
study-specific procedures.
•See Section 10.1.3 for additional information.
Assign participant number 
via the IRTX
Record demography X
Perform clinical 
assessment, including medical history X
Record nonstudy 
vaccinationsXX
Record concomitant 
medication use for treatment of SAEsXX
Obtain oral temperature
prior to study interventionadministrationX
Contraception check, if 
applicableXX •See Section 10.4 for additional information.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 19Visit Identifier Visit 1 Visit 2
Notes Visit Description Study Intervention 
AdministrationFollow-Up After Study Intervention 
Administration
Visit Window (Days) Day 128 to 42 Days After IP 
Administration • See Section 8.4.3 for follow- upAE and SAE assessments.
Perform urine pregnancy 
test for female participants of childbearing potentialX •See Section 8.3.6 for additional information.
Review inclusion and 
exclusion criteriaX •The investigator or designee will inform the participant of the  need 
to use highly effective contraception consistently and correctl y until 
28 days after the last dose of the study intervention and docum ent 
the conversation and the participant’s affirmation in the participant’s chart.
Review continued eligibility X
Assign randomization 
number via the IRTX
Specialty sites: Obtain 
blood sample for 
immunogenicity assessment 
 ~20 mL (for 
immunogenicity)  ~20 mL (for immunogenicity) •Blood samples from participants enrolled at specialty sites 
(n=15/group).
•  
Other sites: Obtain blood 
sample for immunogenicity 
assessment~60 mL ~60 mL •Blood sample for Visit 1 will be collected prior to administrat ion.
Administer study 
interventionX •See Section 6.1 for additional information.
Observe and record acute 
reactions for 30 minutes 
after study intervention administrationX
Provide a participant 
contact cardXPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 20Visit Identifier Visit 1 Visit 2
Notes Visit Description Study Intervention 
AdministrationFollow-Up After Study Intervention 
Administration
Visit Window (Days) Day 128 to 42 Days After IP 
Administration • See Section 8.4.3 for follow- upAE and SAE assessments.
Provide participant with an 
e-diary (device or application), thermometer, and measuring device, and instruct to collect prompted local reactions and systemic 
eventsX •Participants will record in an e-diary prompted local reactions  and 
systemic events occurring within 7 days after administration. Instruct the participant to complete the e-diary from Day 1 thr ough 
Day 7, with Day 1 being the  day of study intervention 
administration. Participants will be instructed to contact the s tudy 
staff or investigator if they experience redness or swelling 
measuring > 20 measuri ng device units, severe pain at the inject ion 
site, or any Grade 4 prompted systemic event.
Review e-diary X •Designated site staff will review e-diary data online at freque nt 
intervals (daily is optimal) for the 7 days following administr ation 
to evaluate participant compliance and reported events as part o f the 
ongoing safety review.
Collect e-diary or assist the participant to delete the 
applicationX •Any e-diary devices given to participants are to be collected a t 
Visit 2.
Record and report AEs and SAEsX-------------------X •AEs include nonserious AEs and SAEs.
•See Section 8.4 for additional information.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 212. INTRODUCTION
S pneumoniae causes invasive disease (eg, meningitis, sepsis, bacteremic pneu monia) and 
noninvasive disease (eg, OM, nonbacteremic pneumonia, sinusitis ) associated with a 
significant healthcare burden, morbidity, and mortality.1The 13-valent pneumococcal 
conjugate vaccine (Prevnar 13, 13vPnC) was licensed more than a  decade ago by the FDA 
and in other countries for use in infants and young children fo r the prevention of 
pneumococcal disease. It was subsequently indicated for prevent ion of pneumonia in adults 
≥18 years of age. 13vPnC has been introduced into national immun ization programs for 
pediatric and adult populations worldwide.
Despite significant reductions in pneumococcal disease followin g use of 13vPnC, a 
significant burden of pneumococcal disease remains. The pneumococ cal 20-valent conjugate 
vaccine (20vPnC, Prevnar 20) was developed to expand protection a gainst IPD and 
pneumonia and has been approved by the FDA and EMA for adults ≥ 18 years of age. It is 
also being developed for pediatric patients. 20vPnC contains the  identical polysaccharide 
conjugates and excipients as 13vPnC, but with additional conjug ate polysaccharides for 
7 additional serotypes.
 
 
 
 
 
2.1. Study Rationale
The purpose of the study is to evaluate the safety and immunogeni city of candidates 
 
 
The study is open-label, so as to allow maximum flexibility for testing and generating the 
. The risk of this approach is low as this is a 1-dose Phase 1 
exploratory study, there is no clinical endpoint in this study, and immunogenicity endpoints 
are not easily biased. The risk of bias in terms of safety asse ssments is also low as the 
participants and investigators will have little preconceived id eas about these candidates.  
.
2.2. Background
Since the  PPD
PPD
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 22 
 
Literature suggests that increased levels of vaccine-elicited a ntibodies may decrease nasal 
carriage.5,6 
Potential mechanisms for enhancing the immunogenicity of
 
•Increases in the polysaccharide dose level may increase the immu ne response. Early in 
the development of Prevnar (7vPnC), the impact of the polysacch aride dose level was 
assessed in an infant study using a 5-valent pneumococcal conju gate vaccine showing 
higher dose levels of some conjugates resulted in higher immuno genicity in infants for 
certain serotypes. Subsequently, in a mixing study with 2 and 4 t imes the standard dose 
of 7vPnC, higher immunogenicity was observed with 4 times the st andard dose for
serotypes in older adults.7In a study conducted by Jackson et al, older adults previously 
vaccinated with PPSV23 were given either a single dose of 13vPn C or 2 concurrent doses 
of 13vPnC. There were no safety issues identified in the study,  and the response to a 
double dose of 13vPnC was higher than that of a single dose for  a majority of the 13vPnC 
serotypes evaluated 8In contrast, in an infant 
study by Rupp et al evaluating an investigational 15-valent pne umococcal conjugate 
vaccine prepared with double the standard dose of polysaccharid e and CRM 197conjugate, 
an increase in immunogenicity was not observed for most serotyp es.9 
 
 
 
 
•  
 
 
 
 
 
•  
 
 
 PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Benefit/Risk Assessment
The investigational candidates have not yet been evaluated in c linical studies; 
therefore, safety data are not available. 
 
. The most common 
AEs noted in adults after vaccination with 20vPnC are primarily r elated to local reactions 
(injection site pain, redness, and swelling) and systemic event s (fever, headache, fatigue, 
joint pain, and muscle pain). Safety review of data from the 3 completed Phase 3 adult trials PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 24has not revealed any unexpected safety concerns. See the 13vPnC and 20vPnC package 
inserts for additional details.
In a dose-ranging study to assess the safety and immunogenicity  of 1-fold, 2-fold, and 4-fold 
higher doses of 7vPnC or 9vPnC compared to a standard dose of P PSV23 conducted in 
adults ≥70 years of age with no history of pneumococcal vaccina tion, local reactions 
occurred at higher frequencies for the 4-fold higher dose level th an with any other dose of 
7vPnC, 9vPnC, or PPSV23.7However, at the 2-fold higher dose, local reactions were not 
statistically significantly higher than the standard dose and th ere were no significant 
differences between groups for systemic events.7
 this study gives dose-ranging safety information for serotypes  with CRM 197. In a 
study by Jackson et al, older adults previously vaccinated with PPSV23 were given either a 
single dose of 13vPnC or 2 concurrent doses of 13vPnC. The resp onse to a double dose of 
13vPnC in previously vaccinated adults was higher than that of a single dose for a majority 
of the 13vPnC serotypes that were evaluated,  
. While double dose of 13vPnC was associated with a higher frequ ency of solicited 
local and systemic AEs than the single dose among those previous ly vaccinated with 
PPSV23, the AEs tended to be mild or moderate and were self-lim ited.8
 
 
 
 
 
 
 
 
 
As with any vaccine, an allergic reaction can occur. The allerg ic reaction can vary from skin 
rash to swelling of the face or lips, wheezing, and/or shortnes s of breath. A severe allergic 
reaction (anaphylactic shock, collapse, or shock-like state [hy potonic-hyporesponsive 
episode]) may also occur. There may also be additional risks re lated to the vaccines 
administered in the study that are not known at this time.
Additional potential risks of clinical significance are present ed in the table in Section 2.3.1 .
More detailed information about the known and expected benefits  and risks and reasonably 
expected AEs of the  candidates may be found in the IB, which is th e SRSD, for this 
study. For 13vPnC and PCV15, the SRSD will be the individual USP I respectively.PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 252.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rational e for Risk Mitigation Strategy
Study Intervention(s): Administration with
The safety profile of the candidates
 
 is not yet fully 
characterized. Local and systemic reactions to the 
candidates may occur (injection site 
redness, injection site swelling, and injection site pain; fever, fatigue, headache, muscle pain, and joint pain) following study intervention.•Eligibility criteria have been selected to ensure 
that only appropriate participants are included in the study (see Section 5 ).
•All study participants will be observed for 
30 minutes after study intervention 
administration.
•E-diary and AE data will be monitored by the 
investigator (or designee) and sponsor.
Study Intervention: Administration with 
The relevant key risks associated with  include: local reactions (injection site pain, redness, and swelling) and systemic events (fever, headache, 
fatigue, joint pain, and muscle pain). Uncommon 
events can include allergic reactions, which may be associated with skin rash, face or lip swelling, wheezing, shortness of breath, or rare severe allergic reactions (eg, anaphylactic shock).The risks are derived from the related 13vPnC
clinical trials and postmarketing data and the 13vPnC USPI.•Eligibility criteria have been selected to ensure 
that only appropriate participants are included in the study (see Section 5 ).
•All study participants will be observed for 
30 minutes after study intervention administration.
•E-diary and AE data will be monitored by the 
investigator (or designee) and sponsor.
Study Intervention: Vaccination with 13vPnC
The relevant key risks associated with 13vPnC 
include: local reactions (injection site pain, redness, 
and swelling) and systemic events (fever, headache, fatigue, joint pain, and muscle pain). Uncommon events can include allergic reactions, which may be associated with skin rash, face or lip swelling, wheezing, shortness of breath, or rare severe allergic reactions (eg, anaphylactic shock).The risks are derived from the related 13vPnC 
clinical trials and postmarketing data and the 
clinical data described in the 13vPnC USPI.•Eligibility criteria have been selected to ensure 
that only appropriate participants are included 
in the study (see Section 5 ).
•All study participants will be observed for 
30 minutes after vaccination.
•E-diary and AE data will be monitored by the 
investigator (or designee) and sponsor.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 26Study Intervention: Vaccination with PCV15
The relevant key risks associated with PCV15 
include: local reactions (injection site pain, redness, and swelling) and systemic events (fever, headache, fatigue, joint pain, and muscle pain).The risks are derived from the USPI for 
Vaxneuvance under the Prescribing Information section.•Eligibility criteria have been selected to ensure 
that only appropriate participants are included in the study (see Section 5 ).
•All study participants will be observed for 
30 minutes after vaccination.
•E-diary and AE data will be monitored by the 
investigator (or designee) and sponsor.
Study Procedures: Venipuncture 
Venipuncture is required to collect immunogenicity data from participants.There is the risk of fainting, and pain, swelling, 
bruising, and infection at the venipuncture site.•Only qualified nurses, physicians, nurse 
practitioners, physician assistants, 
phlebotomists, or medical assistants certified or 
otherwise authorized to draw blood per the standards and procedures of the investigative site, as allowed by institutional, local, and country guidance, will be allowed to draw blood, to minimize local complications.
Other 
Participants will be required to attend healthcare facilities during the global SARS-CoV-2 pandemic.Without appropriate social distancing and PPE, 
there is a potential for increased exposure to 
SARS-CoV-2.•Pfizer will work with sites to ensure an 
appropriate COVID-19 prevention strategy.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 272.3.2. Benefit Assessment
Joining this study will be contributing to research to help othe rs.  
 
A safe and immunogenic pneumococcal conjugate vaccine 
with expanded pneumococcal serotype coverage would fulfill an u nmet need for expanded 
protection against pneumococcal disease.
2.3.3. Overall Benefit/Risk Conclusion
Participants enrolled in this study are in an age group that is  not currently covered by the 
indication for vaccines containing . These participants are rel atively 
healthy and therefore are not recommended for pneumococcal conj ugate vaccines. Receiving 
the  candidates or controls will not interfere with standard of  care for these 
participants. For those with risk factors for pneumococcal vacc ination, the investigator site 
and ICD will inform participants to seek advice from their heal thcare provider regarding the 
need for immunization after the study.
The study will provide the immune impact of  
 
that could potentially benefit adults and 
children.
Taking into account the measures to minimize risk to study partic ipants, the potential risks 
identified in association with  candidates are justified by the a nticipated benefits that 
may be afforded to healthy participants and those at high risk of pneumococcal disease.
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To describe the safety profile of 
candidates in adults 
18 through 49 years of age•Prompted local reactions 
(redness, swelling, and pain at 
the injection site)
•Prompted systemic events 
(fever, headache, fatigue, muscle pain, and joint pain)
•AEs
•SAEsIn participants receiving the study 
intervention from each group, the 
percentage of participants 
reporting: 
•Prompted local reactions 
within 7 days afteradministration
•Prompted systemic events 
within 7 days afteradministration
•AEs within 1 month after
administration
•SAEs within 1 month after
administrationPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 28Objectives Endpoints Estimands
Secondary: Secondary: Secondary: 
To describe the immune responses
elicited by the candidates•OPA titers In participants complying with the 
key protocol criteria (evaluable participants) from each group:
•  OPA GMTs 
1 month after administration
  
 
  
 
 
 
 
 
 
 
4. STUDY DESIGN
4.1. Overall DesignThis is a Phase 1, multicenter, randomized, open-label, active-co ntrol study designed to 
evaluate the safety and immunogenicity of different candidates
 This study
will be conducted at investigator sites in the US. Approximately  405 adults 18 t hrough 
49 years of age with no history of pneumococcal vaccination will  be enrolled. Participants 
will be enrolled and randomized equally to 1 of 9 groups (45 par ticipants per group): 
6 groups will receive 1 of 6 different candidates and 3 groups wil l receive , 
13vPnC, or PCV15 (see Table 1 ) by site-based randomization  
.
 
 PPD PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 29The following preformulated products have been manufactured and w ill comprise the 
following candidates:
 
All formulations include AlPO 4.
The key control group will receive polysaccharide conjugate for  
 as contained in 13vPnC (Prevnar 13) and 20vPnC (Prevnar 20). I n addition, PCV15 
(Vaxneuvance [Merck]), which is also licensed in the US for use in adults, and 13vPnC will 
be included as controls.
Table 1. Study Intervention Groups
GroupCarrier 
Protein ChemistryPolysaccharide 
Dose Dose Volume n
45
45
L4 5
45
45
45
45PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 30Table 1. Study Intervention Groups
GroupCarrier 
Protein ChemistryPolysaccharide 
Dose Dose Volume n
PCV15 (control) N/A N/A 0.5 mL 45
13vPnC (control) CRM 197 RAC 0.5 mL 45
Abbreviations: N/A = not applicable;  
.
On Day 1 (Visit 1), participants will be assessed for eligibili ty, have blood drawn for 
immunogenicity assessments, receive 1 dose of 1 of the candidate s or controls, be 
observed for 30 minutes after administration, and receive safet y follow-up and e-diary 
instructions.
Local reactions (pain, redness, and swelling) occurring at the injection site and systemic 
events (fever, fatigue, headache, muscle pain, and joint pain) will be prompted for and 
collected daily in an e-diary from Day 1 through Day 7 after study  intervention 
administration, where Day 1 is the day of administration. AEs ( including nonserious AEs and 
SAEs) will be assessed for approximately 1 month after study in tervention administration 
(through Visit 2).
At Visit 2 (28-42 days after Visit 1), participants will return  for follow-up. Information will 
be collected from the participants on AEs and e-diary follow-up (as needed), and blood will 
be drawn for immunogenicity assessments.
 
 
 
.
The study duration is estimated to be approximately 2 months.4.2. Scientific Rationale for Study Design
Pfizer is investigating
 
 
 
 Clinical dosage is PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 31managed by volume administered (0.5 or 0.25 mL).  
 
 
The primary control study intervention for the study,  
 
 
The inclusion of 13vPnC as a control will be informative about differences between the 
responses to the current formulation  
 
 
The inclusion of PCV15 will be informative about the response t o the  in 
PCV15, as determined by the Pfizer assays. PCV15 contains capsu lar polysaccharides from 
pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A , 19F, 22F, 23F, and 33F 
individually conjugated to CRM 197.The vaccine formulation contains 2.0 μg of each 
saccharide, except for 4.0 μg of 6B, per 0.5-mL dose.
In adults, administration of a single dose of pneumococcal conjuga te vaccine induces 
immune responses, so the candidates in this study will be evalua ted after a single dose. 
 
 
 
 
 
4.2.1. Diversity of Study Population
This study will be conducted in the US and the diversity strate gy will include high 
performing sites with the potential to support the recruitment of diverse populations. 
The diversity strategy for this study will include the following:
•Selecting sites that have access to diverse participants within  their locale.
•Educating sites about the importance of increasing diversity on  clinical trials and 
Pfizer commitment.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 32•Investigator site recruitment plans that are cocreated with and  include diverse 
recruitment tools and information to support enrollment.
•Real-world data is used to target outreach and potential referr ing physicians.
•Continual monitoring of diverse enrollment to identify addition al opportunities to
include diverse populations.
4.2.2. Choice of Contraception/Barrier Requirements
Human reproductive safety data are not available for the candid ate formulations, but there is 
no suspicion of human teratogenicity based on the intended phar macology of the compound.
Therefore, the use of a highly effective method of contraceptio n is required (see Appendix 4 ).
4.3. Justification for Dose
 
 
 
 
 
 
The polysaccharide conjugates and CRM 197have 
been tested at up to 4 times the standard dose in adults and up  to 2 times the standard dose in 
infants. In dose-ranging studies with investigational vaccines and with 13vPnC, immune 
responses were at times higher, but not consistently, leaving d ose-response to remain in 
question. The safety profile was acceptable even at the highest  doses in these studies.7,8,9
 
.
 
No significant adverse effects were seen with animal data in 
rats at the highest dose range.
4.4. End of Study Definition
The end of the study is defined as the date of the last visit o f the last participant in the study.
A participant is considered to have completed the study if they  have completed all periods of 
the study, including the last visit.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate parti cipants are enrolled, including 
participants across diverse and representative racial and ethni c backgrounds. If a PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 33prescreening tool is utilized for study recruitment purposes, i t will include collection of 
information that reflects the enrollment of a diverse participa nt population including, where 
permitted under local regulations, age, sex, race, and ethnicit y. The following eligibility 
criteria are designed to select participants for whom participa tion in the study is considered 
appropriate. All relevant medical and nonmedical conditions sho uld be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if a ll of the following criteria apply:
Age and Sex:1. Male or female participants ≥18 and ≤49 years of age at the time of consent.
•Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female
(Section 10.4.2 ) participants.
Disease Characteristics:2. Participants who are willing and able to comply with all sche duled visits, the 
investigational plan, laboratory tests, lifestyle considerations,  and other study procedures.
3. Adults determined by clinical assessment, including medical h istory and clinical 
judgment, to be eligible for the study, including adults with p reexisting stable disease, 
defined as disease not requiring significant change in therapy or hospitalization for 
worsening disease, within 12 weeks before receipt of study inte rvention.
4. Participants who can be expected to be available for the dura tion of the study and can be 
contacted by telephone during study participation.
5. Female participants of childbearing potential or male partici pants who are able to father 
children and are willing to use acceptable methods of contracep tion for at least 28 days 
after the dose of study intervention; or female participants no t of childbearing potential; 
or male participants not able to father children.
Note: Female participants of nonchildbearing potential must mee t the criteria described in 
the WOCBP ( Section 10.4.3 ) section of the protocol.
Other Inclusion Criteria:6. Participants capable of giving signed informed consent, which  includes compliance with 
the requirements and restrictions listed in the ICD and in this  protocol.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 345.2. Exclusion Criteria
Participants are excluded from the study if any of the followin g criteria apply:
Medical Conditions:
1. History of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaphylaxis) to any component in pneumococcal con jugate vaccines and 
any other diphtheria toxoid–containing vaccine.
2. Serious chronic disorder, including metastatic malignancy, se vere COPD requiring 
supplemental oxygen, end-stage renal disease with or without di alysis, cirrhosis of the 
liver, clinically unstable cardiac disease, or any other disord er that in the 
investigator’s opinion would make the participant inappropriate for entry into the 
study.
3. Other medical or psychiatric condition including recent (with in the past year) or 
active suicidal ideation/behavior or laboratory abnormality tha t may increase the risk 
of study participation or, in the investigator’s judgment, make  the participant 
inappropriate for the study.
4. History of microbiologically proven invasive disease caused b y S pneumoniae .
5. Known or suspected immunodeficiency or other conditions assoc iated with 
immunosuppression, including, but not limited to, immunoglobuli n class/subclass 
deficiencies, generalized malignancy, HIV infection, leukemia, lymphoma, or organ 
or bone marrow transplant.
6. Bleeding diathesis or condition associated with prolonged ble eding that would, in the 
opinion of the investigator, contraindicate intramuscular injec tion.
7. Congenital, functional, or surgical asplenia.8. Current febrile illness (body temperature ≥100.4°F [≥38.0°C])  or other acute illness 
within 48 hours before study intervention administration.
9.Pregnant female participants or breastfeeding female participan ts (known or 
suspected).
Prior/Concomitant Therapy:
10. Previous vaccination with any licensed or investigational pn eumococcal vaccine, or 
planned receipt of any licensed or investigational pneumococcal  vaccine through 
study participation.
11. Currently receives treatment with immunosuppressive therapy,  including cytotoxic 
agents or systemic corticosteroids, or planned receipt through the last blood draw PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 35(Visit 2). Participants may not be enrolled if corticosteroids were administered within 
28 days of study intervention administration. Inhaled/nebulized,  intra-articular, 
intrabursal, or topical (skin, eyes, or ears) corticosteroids a re permitted.
12. Receipt of blood/plasma products or immunoglobulin within th e 60 days before study 
intervention administration, or planned receipt during study pa rticipation.
13. Receipt of any inactivated or otherwise nonlive vaccine with in 14 days or any live 
vaccine within 28 days before administration of study intervent ion.
Prior/Concurrent Clinical Study Experience:
14. Participation in other studies involving investigational dru gs, investigational vaccines 
(except for investigational pandemic vaccines recommended and authorized in this 
population for emergency use ), or investigational devices within 28 days prior to 
study entry and/or during study participation. Participation in  purely observational 
studies is acceptable.
Diagnostic Assessments:Not applicable.Other Exclusion Criteria:
15. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by the investigator, a nd sponsor and sponsor 
delegate employees directly involved in the conduct of the stud y and their family 
members.
5.3. Lifestyle Considerations
5.3.1. ContraceptionThe investigator or their designee, in consultation with the pa rticipant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception me thods (see Appendix 4 ,
Section 10.4.4 ) and will confirm that the participant has been instructed in its consistent and 
correct use. At time points indicated in the SoA, the investigator or designee will inform the 
participant of the need to use acceptable effective contraception consistently and correctly 
and document the conversation and the participant’s affirmation  in the participant’s chart.
Participants need to affirm their consistent and correct use of  at least 1 of the selected 
methods of contraception, considering that their risk for pregnan cy may have changed since 
the last visit.
In addition, the investigator or designee will instruct the par ticipant to call immediately if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol-specified method, including if the participa nt will no longer use abstinence PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 36as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
5.4. Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but 
are not subsequently randomly assigned to study intervention/enro lled in the study. A 
minimal set of screen failure information is required to ensure  transparent reporting of screen 
failure participants to meet the CONSORT publishing requirement s and to respond to queries 
from regulatory authorities. Minimal information includes demogr aphy, screen failure 
details, and any SAE.
Individuals who do not meet the criteria for participation in t his study (screen failure) may 
not be rescreened.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/ Administration of 
Study Intervention 
Not applicable.
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study interventions are all prespecified investigational and no ninvestigational medicinal 
products, medical devices, and other interventions (eg, surgica l and behavioral) intended to 
be administered to the study participants during the study cond uct.
For the purposes of this protocol, study intervention refers to investigational products
and noninvestigational products (13vPnC and 
PCV15).
Study interventions will be provided as 4 preformulated products  in vials and 2 products in 
PFSs, as outlined below:
•   
•   
•   
•  
•13vPnC (Prevnar 13) (PFS)
•PCV15 (Vaxneuvance) (PFS)PPD
PPD
PPD
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 37The study interventions  
will be prepared by adjusting the volume extracted from the prefor mulated 
products in vials to a dose of either 0.25 mL or 0.5 mL. The stud y intervention  
will be prepared by adjusting the volume extracted from the pre formulated product in the vial 
to a dose of 0.5 mL. The PFSs will be administered as 0.5-mL doses for 13vPnC and PCV15.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 386.1. Study Intervention(s) Administered
Study Intervention(s)
Intervention 
name 
 
 
 
  
  
 
 
  
 
 
 
 
 13vPnC 
(Prevnar 13)
0.5-mL suspension for injection PCV15 
(Vaxneuvance)
(pneumococcal 
15-valent conjugate 
vaccine)
suspension for injection
Arm name
(group of 
participants receiving a specific 
intervention or 
no intervention) 
group, n=45 
group, n=45 
group, n= 45 group, 
n=45 
group, n=45 
group, n=45 
monovalent 
control group, n=4513vPnC control 
group, n=45PCV15 control 
group, n=45
Dosage level(s)
  
  
    
  
 2.2 μg for all 
serotypes except 
6B; 4.4 μg for serotype 6B per 0.5-mL dose2.0 μg for all 
serotypes except 
6B; 4.0 μg for serotype 6B per 0.5-mL dose
Dose volume 0.5 mL 0.5 mL
Type Biologic Biologic Biologic Biologic Biologic Biologic Biologic Biol ogic BiologicPPDPPD PPD PPD PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 39Study Intervention(s)
Dose formulation Suspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSuspension for 
injection in a 
single-use vialSterile liquid 
suspension 
formulation in a PFS containing saccharides from 
pneumococcal 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 
19F, and 23F 
individually conjugated to CRM
197Sterile liquid 
suspension 
formulation in a PFS containing saccharides from 
pneumococcal 
serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, 22F, 
23F, and 33F individually conjugated to CRM
197
Route of administrationIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injectionIntramuscular 
injection
Use Experimental Experimental Experimental Experimental Experimental Experimental Control Control Control
IMP or 
NIMP/AxMPIMP IMP IMP IMP IMP IMP IMP NIMP NIMP
Sourcing Provided 
centrally by the sponsor Provided 
centrally by the sponsorProvided 
centrally by the sponsorProvided 
centrally by the sponsorProvided 
centrally by the sponsorProvided 
centrally by the sponsorProvided 
centrally by the sponsorProvided centrally 
by the sponsorProvided 
centrally by the sponsor
Packaging and labelingStudy 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study 
intervention 
will be 
provided in vials. Each vial will be labeled as required per 
country 
requirement.Study 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study 
intervention will 
be provided in 
vials. Each vial will be labeled as required per country 
requirement.Study intervention 
will be provided 
in a PFS. Each 
PFS will be labeled as required per country 
requirement.Study 
intervention will 
be provided in a 
PFS. Each PFS will be labeled as required per country 
requirement.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 40Study intervention will be supplied by Pfizer as PFSs or vials a s open-label supply. Each vial 
will be packaged in a carton, with a label and tamper-evident se al, and will be labeled as 
required per country requirement. Each syringe will be packaged  in a commercial carton and 
will be labeled as required per country requirement. Refer to t he IPM for additional details.
6.1.1. Administration
All participants will be administered 1 of the  candidates  
or a control PCV15, or 13vPnC).
Study intervention will be provided by the sponsor to the study sites. A 0.25-mL or 0.5-mL
dose of 1 of the preformulated products or a 0.5-mL dose of 1 of the controls will be 
administered intramuscularly in the deltoid muscle of the nondo minant arm by a site staff 
member or designee. The description of the  candidates and contro ls can be found in
the IPM.
Standard vaccination practices must be observed and vaccine mus t not be injected into blood 
vessels. Appropriate medication and other supportive measures f or management of an acute 
hypersensitivity reaction should be available in accordance wit h local guidelines for standard 
immunization practices.
Administration of study interventions should be performed by an appropriately qualified, 
GCP-trained, and vaccine-experienced member of the study staff (eg, physician, nurse, 
physician’s assistant, nurse practitioner, pharmacist, or medic al assistant) as allowed by local, 
state, and institutional guidance.
Study intervention administration details will be recorded on th e CRF.
6.1.2. Medical Devices
1. In this study, medical devices being deployed are the PFSs co ntaining 13vPnC and 
PCV15.
2. Instructions for medical device use are provided in the IPM or  in the package insert.
3. All medical device deficiencies (including malfunctions of the  device, use error and 
inadequate labelling) must be detected, documented, and reporte d by the study 
personnel throughout the study. Please refer to Section 8.4.9 for details.
6.2. Preparation, Handling, Storage, and Accountability
The investigator or an approved representative, eg, pharmacist,  will ensure that all study 
interventions are stored in a secured area with controlled acces s under required storage 
conditions and in accordance with applicable regulatory require ments.
Study interventions should be stored in their original containe rs and in accordance with the 
labels.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 411. The investigator or designee must confirm that appropriate con ditions (eg, 
temperature) have been maintained during transit for all study interventions received 
and any discrepancies are reported and resolved before use of t he study intervention.
2. Only participants enrolled in the study may receive study int ervention and only 
authorized site staff may supply, prepare, and/or administer st udy intervention.
3. All study interventions must be stored in a secure, environmen tally controlled, and 
monitored (manual or automated recording) area in accordance wit h the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonwork ing days must 
indicate the minimum and maximum temperatures since previously do cumented upon 
return to business.
4. Any excursions from the study intervention label storage cond itions should be 
reported to Pfizer upon discovery along with actions taken. The  site should actively 
pursue options for returning the study intervention to labeled storage conditions, as 
soon as possible. Once an excursion is identified, the study in tervention must be 
quarantined and not used until Pfizer provides permission to us e the study 
intervention. Specific details regarding the excursion definition  and information to
report for each excursion will be provided to the site in the I PM.
5. Any storage conditions stated in the SRSD will be superseded by the storage 
conditions stated on the label.
6. Study interventions should be stored in their original contain ers.
7. The investigator, institution, head of the medical institutio n (where applicable), or 
authorized site staff is responsible for study intervention acc ountability, 
reconciliation, and record maintenance (ie, receipt, reconcilia tion, and final 
disposition records), such as the IPAL or sponsor-approved equi valent. All study 
interventions will be accounted for using a study intervention ac countability 
form/record.
8. Further guidance and information for the final disposition of  unused study 
interventions are provided in the IPM. All destruction must be a dequately 
documented. If destruction is authorized to take place at the i nvestigator site, the 
investigator must ensure that the materials are destroyed in co mpliance with 
applicable environmental regulations, institutional policy, and  any special instructions 
provided by Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery as described in the IPM.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 426.2.1. Preparation and Dispensing
See the IPM for instructions on how to prepare the study interve ntion for administration. 
Study intervention should be prepared and dispensed by an appro priately qualified and 
experienced member of the study staff (eg, physician, nurse, ph ysician’s assistant, nurse 
practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and 
institutional guidance. A second staff member will verify the p reparation and dispensing.
The study intervention will be prepared by qualified site perso nnel according to the IPM.
6.3. Assignment to Study Intervention
Allocation (randomization) of participants to intervention groups  will proceed through the 
use of an IRT system (IWR). The site personnel (study coordinato r or specified designee) 
will be required to enter or select information including but n ot limited to the user’s ID and 
password, the protocol number, and the participant number.
The site personnel will then be provided with a randomization nu mber corresponding to the 
assigned intervention group, and DU or container number(s) when study intervention and 
proper dose is being supplied via the IRT system. The IRT system will provide a 
confirmation report containing the participant number, randomiza tion number, and DU or 
container number assigned. The confirmation report must be stor ed in the site’s files.
The site will record the study intervention assignment on the a pplicable CRF, if required.
Study intervention will be dispensed at the study visits summari zed in the SoA.
The study-specific IRT reference manual and IPM will provide the  contact information and 
further details on the use of the IRT system.
This is an open-label study. The investigator’s knowledge of th e intervention assignment 
must not influence the decision to enroll a particular particip ant or affect the order in which 
participants are enrolled. Potential bias will be reduced by th e following steps: central IRT 
system for randomization
6.4. Blinding
This is an open-label study.
6.4.1. Blinding of Participants
Participants will be unblinded to their assigned study interven tion.
6.4.2. Blinding of Site Personnel
Investigators and other site staff will be unblinded to partici pants’ assigned study 
intervention.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 436.4.3. Blinding of the Sponsor
Sponsor staff will be unblinded to participants’ assigned study  intervention. All laboratory 
testing personnel performing serology assays will remain blinde d to study intervention 
assigned/received throughout the study.
6.5. Study Intervention Compliance
When participants are dosed at the site, they will receive stud y intervention directly from the 
investigator or designee, under medical supervision. The date a nd time of each dose 
administered in the clinic will be recorded in the source docum ents and recorded in the CRF. 
The dose of study intervention and study participant identifica tion will be confirmed at the 
time of dosing by a member of the study site staff other than t he person administering the 
study intervention.
The site will complete the required dosage preparation record l ocated in the IPM. The use of 
the preparation record is required. The use of alternative prep aration records must be 
approved by the Sponsor’s clinical research pharmacist prior to  its use.
6.6. Dose Modification
Not applicable.
6.7. Continued Access to Study Intervention After the End of the Study
This exploratory study is describing the tolerability and immunog enicity of 6  
candidates. There will be no further intervention provided to par ticipants at the end 
of their study participation. It is expected that participants wil l be treated as required with 
standard-of-care treatments, as advised by their usual care phy sician.
6.8. Treatment of Overdose
For this study, any dose of study intervention greater than 0.5  mL of study intervention
within a 24-hour time period will be considered an overdose. If the participant assigned to 
0.25 mL has inadvertently been administered a 0.5-mL dose, this will not be considered an 
overdose but will be a dosing error and a protocol deviation requ iring communication to the 
sponsor ( Section 8.4.10 ).
There is no specific treatment for an overdose.In the event of an overdose, the investigator should:
1. Contact the study medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs as medically  appropriate and at 
least until the next scheduled follow-up.
3. Document the quantity of the excess dose as well as the durati on of the overdose in 
the CRF.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 444. Overdose is reportable to Pfizer Safety only when associated with an SAE.
6.9. Prior and Concomitant Therapy
The name and date of administration for all nonstudy vaccinatio ns received from the time of 
signing of the ICD to Visit 2 will be collected and recorded in the CRF.
Medications taken to treat SAEs from the time of signing of the  ICD through Visit 2 will be 
recorded in the CRF.
6.9.1. Prohibited During the Study
•Receipt of any investigational vaccines, drugs, or medical devi ces is prohibited 
during study participation.
•Receipt of nonstudy pneumococcal vaccine is prohibited during s tudy participation.
•Receipt of any other licensed nonstudy vaccine is prohibited du ring study 
participation, except as noted in Section 6.9.2.
•Receipt of blood/plasma products, immunoglobulins, and/or immun osuppressive 
therapy (including a ≥14-day course of systemic corticosteroids ) is prohibited during 
study participation.
6.9.2. Permitted During the Study
•Prescription and nonprescription medications, vitamins, mineral s, and herbal 
remedies are permitted during participation in the study.
•Inhaled/nebulized, topical (eg, skin, eyes, ears), or localized  injections of 
corticosteroids (eg, intra-articular or intrabursal administrat ion) are permitted during 
study participation.
•Licensed inactivated influenza vaccine may be given >14 days af ter study 
intervention administration (Visit 1).
•If medically necessary (eg, during a pandemic), a COVID-19 vaccin e, or tetanus 
vaccine required following wound care, may be given during the st udy, with 
preference for >7 days after study intervention administration (Visit 1), if feasible.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionSince this is a single-dose study, this section is not applicab le.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 457.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at their o wn request. Reasons for 
discontinuation from the study include the following:
•Refused further study procedures; 
•Lost to follow-up; 
•Death; 
•Study terminated by sponsor; 
•AE; 
•Physician decision; 
•Pregnancy; 
•Protocol deviation; 
•Screen failure; 
•Participant request; 
•Vaccination error without associated AE; 
•No longer meets eligibility criteria; 
•Other.
If a participant withdraws from the study, they may request dest ruction of any remaining 
samples taken and not tested, and the investigator must document a ny such requests in the 
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations wi ll be performed and no 
additional data will be collected. The sponsor may retain and c ontinue to use any data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent
Participants who request to discontinue will remain in the stud y and must continue to be 
followed for protocol-specified follow-up procedures. The only exception to this is when a 
participant specifically withdraws consent for any further conta ct with them or persons 
previously authorized by the participant to provide this informa tion. Participants should 
notify the investigator in writing of the decision to withdraw consent from future follow-up, PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 46whenever possible. The withdrawal of consent should be explaine d in detail in the medical 
records by the investigator and entered on the appropriate CRF page. In the event that vital 
status (whether the participant is alive or dead) is being measu red, publicly available 
information should be used to determine vital status only as ap propriately directed in 
accordance with local law.
7.3. Lost to Follow-Up
A participant will be considered lost to follow-up if the parti cipant repeatedly fails to return 
for scheduled visits and is unable to be contacted by the study  site.
The following actions must be taken if a participant fails to at tend a required study visit:
•The site must attempt to contact the participant and reschedule  the missed visit as 
soon as possible. Counsel the participant on the importance of m aintaining the 
assigned visit schedule, and ascertain whether the participant w ishes to and/or should 
continue in the study;
•Before a participant is deemed lost to follow-up, the investiga tor or designee must 
make every effort to regain contact with the participant (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’ s last known mailing 
address or local equivalent methods). These contact attempts sho uld be documented 
in the participant’s medical record;
•Should the participant continue to be unreachable, the particip ant will be considered 
to have withdrawn from the study.
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative ProceduresThe investigator (or an appropriate delegate at the investigato r site) must obtain a signed and 
dated ICD before performing any study-specific procedures.
The date of birth will be collected to critically evaluate the immune response and safety 
profile by age.
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those spe cified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria. The investigator wi ll maintain a screening log to 
record details of all participants screened and to confirm eligi bility or record reasons for 
screening failure, as applicable.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 47Every effort should be made to ensure that protocol-required te sts and procedures are 
completed as described. However, it is anticipated that from ti me to time there may be 
circumstances outside the control of the investigator that make  it unfeasible to perform the 
test. In these cases, the investigator must take all steps nece ssary to ensure the safety and 
well-being of the participant. When a protocol-required test ca nnot be performed, the 
investigator will document the reason for the missed test and a ny corrective and preventive 
actions that they have taken to ensure that required processes a re adhered to as soon as 
possible. The study team must be informed of these incidents in  a timely manner.
For samples being collected and shipped, detailed collection, p rocessing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
8.2. Efficacy and/or Immunogenicity Assessments
Blood will be collected before study intervention administratio n (Visit 1) and approximately 
1 month after administration (Visit 2) to assess immunogenicity .
Approximately 135 participants (approximately n=15/group) will be  enrolled at specific 
investigator sites,  
and approximately 20 mL of blood will be collected for sera 
measurements of immunogenicity (OPA titers and IgG concentratio ns) at each time point 
(Visit 1 and Visit 2). The remaining approximately 270 particip ants enrolled at other sites 
(approximately n=30/group) will have approximately 60 mL of blood  collected for 
measurement of immunogenicity (OPA titers and IgG concentration s) at each time point 
(Visit 1 and Visit 2).
 
 
Immune Responses
OPA titers and IgG concentrations  will be measured in sera 
collected at Visits 1 and 2.
 
 
 
 PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 488.2.1. Biological Samples 
Blood samples will be used only for scientific research. Each sa mple will be labeled with a 
code so that the laboratory analyst testing the samples will no t know the participant’s 
identity, study visit, or study cohort associated with the samp le. Samples that remain after 
performing assays outlined in the protocol may be stored by Pfi zer. Unless a time limitation 
is required by local regulations or ethical requirements, the s amples will be stored for up to 
15 years after the end of the study and then destroyed.  
 
No testing of the participant’s genetic material will be perfor med,  
 
The participant may request that their samples, if still identif iable, be destroyed at any time; 
however, any data already collected from those samples will sti ll be used for this research. 
The biological samples may be shared with other researchers as long as confidentiality is 
maintained and no testing of the participant’s genetic material  is performed, 
 
8.3. Safety Assessments
A clinical assessment, including medical history and measuremen t of oral temperature, will 
be performed on all participants prior to receipt of study inte rvention administration at Visit 1 
to determine participant eligibility and to establish a clinica l baseline. Significant medical 
history and significant findi ngs from any physical examination (if performed) will be 
recorded as medical history in the CRF. Temperature measurement prior to administration at 
Visit 1 will be documented and recorded in the CRF.
The participant will be observed for 30 minutes after study int ervention administration, and 
any reactions occurring during that time will be recorded as AE s.
Prompted e-diary events, including local reactions (redness, sw elling, and pain at the 
injection site) and systemic events (fever, headache, fatigue, muscle pain, and joint pain) that 
occur from Days 1 through 7, where Day 1 is the day of study in tervention administration, 
are graded as noted in Table 2 and Table 3 .AEs and SAEs will be collected from the signing 
of the ICD through Visit 2.
Planned time points for all safety assessments are provided in theSoA. Unscheduled safety 
measurements may be obtained at any time during the study to as sess any perceived safety 
issues.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 498.3.1. Participant Electronic Diary
Participants will be asked to monitor and record local reaction s and systemic events after 
vaccination (Day 1 through Day 7, where Day 1 is the day of study  intervention 
administration) using an e-diary through an application install ed on a provisioned device or 
on the participant’s own personal device. This allows recording  of these assessments only 
within a fixed time window, thus providing the accurate represen tation of the participant’s 
experience. Data reported in the e-diary will be transferred el ectronically to the e-diary 
vendor, where they will be available for review by investigator s, their appropriately qualified 
designees, and sponsor staff at all times via an internet-based  portal. At intervals agreed to by 
the vendor and Pfizer, these data will be transferred electroni cally to Pfizer for analysis and 
reporting.
The daily e-diary data will not be captured in the CRF. However , if a participant is 
withdrawn because of prompted events reported in the e-diary, t he event(s) should be 
recorded on the AE page of the CRF, regardless of whether the i nvestigator considers the 
event(s) to be clinically significant.
The investigator or designee must obtain stop dates for any loc al reactions and specific 
systemic events that were ongoing on the last day that the e-di ary was completed. The stop 
dates should be entered in the CRF.
Investigators (or an appropriately qualified designee) are requ ired to review the e-diary data 
online at frequent intervals (daily is optimal) to evaluate par ticipant compliance and reported 
events as part of the ongoing safety review.
8.3.2. Grading Scale for Prompted Events
The grading scales used in this study to assess prompted events  as described below are based 
on concepts outlined in the FDA CBER guidelines on toxicity gra ding scales for healthy 
adult volunteers enrolled in preventive vaccine clinical trials .26
8.3.2.1. Local Reactions
From Day 1 through Day 7 following study intervention administr ation at Visit 1, where 
Day 1 is the day of study intervention administration, participa nts will be asked to assess 
redness, swelling, and pain at the injection site and to record the symptoms in the e-diary in 
the evening. Redness and swelling will be measured and recorded  in measuring device 
(caliper) units (range: 1 to 21+) and then categorized during a nalysis as mild, moderate, or 
severe based on the grading scale in Table 2 . Measuring device units can be converted to 
centimeters according to the following scale: 1 measuring devic e unit = 0.5 cm. Pain at the 
study intervention injection site will be assessed by the partic ipant as mild, moderate, or 
severe according to the grading scale in Table 2 . The participant will be prompted to contact 
the investigator if he/she experiences a severe (Grade 3 or abo ve) local reaction to assess the 
reaction and perform an unscheduled assessment or visit as appr opriate. Only an investigator 
is able to classify a participant’s local reaction as Grade 4, after physical examination of the 
participant or documentation from another medically qualified s ource (eg, emergency room PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 50or hospital record). If a participant experiences a Grade 4 loc al reaction, the investigator must 
immediately notify the sponsor. Site staff will educate the par ticipants regarding signs and 
symptoms that would prompt site contact. Grade 4 reactions will  be collected as AEs on the 
CRF. The event will be graded using the AE intensity grading sca le (Section 10.3.3 ).
The procedure for notification of the sponsor is provided in th e investigator site file or 
equivalent.
Table 2. Grading Scales for Local Reactions
Mild
Grade 1Moderate
Grade 2Severe
Grade 3aGrade 4b
Redness 5 to 10 measuring 
device units
=>2.0 to 5.0 cm11 to 20 measuring
device units
=>5.0 to 10.0 cm>20 measuring 
device units
=>10.0 cmNecrosis or 
exfoliative 
dermatitis
Swelling 5 to 10 measuring 
device units
=
>2.0 to 5.0 cm11 to 20 measuring 
device units
=
>5.0 to 10.0 cm>20 measuring 
device units
=
>10.0 cmNecrosis
Pain at injection site Does not interfere 
with activityInterferes with 
activityPrevents daily 
activitycEmergency room visit or hospitalization for severe injection site 
pain
Note: If the size of the redness and/or swelling falls between 2 measuring device units, the higher measuring 
device unit number will be recorded in the e-diary.
a. Participants experiencing Grade 3 local reactions are require d to contact the investigator site. In the event 
that the participant does not call, the investigator will call the participant.
b. Grade 4 assessment should be made by the investigator; Grade 4 local reactions will not be collected in 
the e-diary but will be collected as AEs on the CRF. The intensit y of the local reaction should be graded 
using the AE intensity grading scale in Section 10.3.3 .
c. Prevents daily activity, eg, results in missed days of school  or work or is otherwise incapacitating.
8.3.2.2. Systemic Events
From Day 1 through Day 7 following study intervention administrat ion at Visit 1, where 
Day 1 is the day of study intervention administration, participa nts will be asked to assess 
headache, fatigue, muscle pain, and joint pain and to record th e symptoms in the e-diary in 
the evening. The symptoms will be assessed by the participant a s mild, moderate, or severe 
according to the grading scale in Table 3 below. Participants will also be instructed to contact 
site staff or the investigator if they experience any severe (G rade 3 or above) prompted 
systemic event within 7 days after administration. Study staff m ay also contact the participant 
to obtain additional information on Grade 3 events entered into  the e-diary.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 51Only an investigator is able to classify a participant’s system ic event as Grade 4, after 
physical examination of the participant or documentation from a nother medically qualified 
source (eg, emergency room or hospital record) or telephone con tact with the participant. If a 
participant experiences a Grade 4 systemic event, the investiga tor must immediately notify 
the sponsor. Grade 4 events will be collected as an AE on the C RF. The event will be graded 
using the AE intensity grading scale (See Section 10.3.3 ).
The procedure for notification of the sponsor is provided in th e investigator site file or 
equivalent.
Table 3. Grading Scales for Systemic Events
Mild
Grade 1Moderate
Grade 2Severe
Grade 3aGrade 4b
Fatigue (tiredness) Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or hospitalization for 
severe fatigue
Headache Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or hospitalization for severe headache
Muscle pain Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or hospitalization for severe muscle pain
Joint pain Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospitalization for 
severe joint pain
a. Prevents daily routine activity, eg, results in missed days o f school or work or is otherwise incapacitating; 
includes use of narcotics for analgesia.
b. Grade 4 assessment should be made by the investigator; Grade 4 systemic events will not be collected in 
the e-diary but will be collected as AEs on the CRF. The intensit y of the systemic event should be graded 
using the AE intensity grading scale in Section 10.3.3 .
8.3.2.2.1. Fever
In order to record information on fever, a digital thermometer will be given to the participant 
with instructions on how to measure oral temperature at home. Te mperature will be collected 
in the evening daily for 7 days following each study interventio n administration (Days 1 
through 7, where Day 1 is the day of study intervention administ ration) and at any time 
during the 7 days that fever is suspected. The highest temperat ure for each day will be 
recorded in the e-diary. In the event of a fever on Day 7, temp erature will be collected daily 
until the fever has resolved (1 day of temperature <100.4°F [<3 8.0°C]) in order to collect a PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 52stop date in the CRF. Participants reporting a fever >102.0°F (> 38.9°C) will be prompted to 
contact the study site. Study staff may also contact the partic ipant to obtain additional 
information if a temperature of >102.0°F (>38.9°C) is entered i nto an e-diary. Temperature 
will be measured and recorded to 1 decimal place.
Temperatures obtained in degrees Fahrenheit will be programmatic ally converted to degrees 
Celsius for reporting. Fever will be grouped into ranges for th e analysis according to Table 4.
Table 4. Ranges for Fever
≥38.0°C to 38.4°C
>38.4°C to 38.9°C
>38.9°C to 40.0°Ca
>40.0°Ca
Note: Fever is defined as a temperature of ≥38.0°C.
a. Participants reporting a fever >102.0°F (>38.9°C) will be pro mpted to contact the study site.
8.3.3. Physical Examinations
Physical examination findings collected during the study will b e considered source data and 
will not be required to be reported, unless otherwise noted. Any  untoward physical 
examination findings that are identified during the active coll ection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to 8.4.3 .
8.3.4. Vital Signs
The participant’s oral temperature will be measured prior to st udy intervention 
administration.
Any untoward vital sign findings that are identified during the  active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1 to 8.4.3 .
8.3.5. Clinical Safety Laboratory Assessments
Clinical safety laboratory assessments will not be collected in  this study.
8.3.6. Pregnancy Testing
Following screening, pregnancy tests may be urine or serum test s, but must have a sensitivity 
of at least 25 mIU/mL. Pregnancy tests will be performed in WOC BP at the times listed in 
theSoA, immediately before the administration of each vaccine dose. A  negative pregnancy 
test result will be required prior to the participant’s receivi ng the study intervention. 
Pregnancy tests may also be repeated if requested by IRBs/ECs o r if required by local 
regulations. In the case of a positive confirmed pregnancy, the  participant will be withdrawn 
from administration of study intervention and from the study.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 538.4. Adverse Events, Serious Adverse Events, and Other Safety Rep orting
The definitions of an AE and an SAE can be found in Appendix 3 .
The definitions of device-related safety events (ADEs and SADEs ) ca.n be found in 
Appendix 8 . Device deficiencies are covered in Section 8.4.9.
AEs may arise from symptoms or other complaints reported to the  investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, o r the participant's legally 
authorized representative), or they may arise from clinical fin dings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and any qualified designees are responsible fo r detecting, documenting, and 
recording events that meet the definition of an AE or SAE and r emain responsible to pursue 
and obtain adequate information both to determine the outcome a nd to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study (see Section 7.1 ).
During the active collection period as described in Section 8.4.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by Pfizer Safety  to obtain specific follow-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Infor mation
The time period for actively eliciting and collecting AEs and S AEs (“active collection 
period”) for each participant begins from the time the participa nt provides informed consent, 
which is obtained before the participant’s participation in the  study (ie, before undergoing 
any study-related procedure and/or receiving study intervention ), through and including 
Visit 2.
Follow-up by the inve stigator continues throughout the active c ollection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level accept able to the investigator.
When a clinically important AE remains ongoing at the end of th e active collection period, 
follow-up by the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection  period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when cons ent is withdrawn.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 54If a participant permanently discontinues or temporarily disconti nues study because of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE r eported using the 
Vaccine SAE Reporting Form.
Investigators are not obligated to actively seek information on  AEs or SAEs after the 
participant has concluded study participation. However, if the i nvestigator learns of any SAE, 
including a death, at any time after a participant has complete d the study, and they consider 
the event to be reasonably related to the study intervention, t he investigator must promptly 
report the SAE to Pfizer using the Vaccine SAE Reporting Form.
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection  period as described in
Section 8.4.1 are reported to Pfizer Safety on the Vaccine SAE Reporting Form immediately 
upon awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the spon sor within 
24 hours of its being available.
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during t he active collection period, 
which begins after obtaining informed consent as described in Section 8.4.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by the participant.
As part of ongoing safety reviews conducted by the sponsor, any  nonserious AE that is 
determined by the sponsor to be serious will be reported by the  sponsor as an SAE. To assist 
in the determination of case seriousness, further information m ay be requested from the 
investigator to provide clarity and understanding of the event i n the context of the clinical 
study.
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of  AEs and SAEs and the 
procedures for completing and transmitting SAE reports are prov ided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and /or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferr ed method to inquire about 
AE occurrences.
8.4.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required  to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the  event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3 ).PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 55In general, follow-up information will include a description of  the event in sufficient detail to 
allow for a complete medical assessment of the case and indepen dent determination of 
possible causality. Any information relevant to the event, such  as concomitant medications 
and illnesses, must be provided. In the case of a participant de ath, a summary of available 
autopsy findings must be submitted as soon as possible to Pfize r Safety.
Further information on follow-up procedures is provided in Appendix 3 .
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE  is essential so that legal 
obligations and ethical responsibilities toward the safety of p articipants and the safety of a 
study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local  regulatory authority and other 
regulatory agencies about the safety of a study intervention un der clinical investigation. The 
sponsor will comply with country-specific regulatory requiremen ts relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigat ors.
Investigator safety reports must be prepared for SUSARs accordin g to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives SUSARs or other specific safety inf ormation (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify the IRB/EC, if appropriate according to lo cal requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Brea stfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the  study as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, family members, and othe rs who may be exposed. An 
environmental exposure may include EDP, EDB, and occupational exp osure.
Any such exposures to the study intervention under study are repo rtable to Pfizer Safety 
within 24 hours of investigator awareness.
8.4.5.1. Exposure During Pregnancy
An EDP occurs if:
•A female participant is found to be pregnant while receiving or  after discontinuing 
study intervention.
•A male participant who is receiving or has discontinued study i ntervention 
inseminates a female partner.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 56•A female nonparticipant is found to be pregnant while being expo sed or having been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:
•A female family member or healthcare provider reports that she i s pregnant after 
having been exposed to the study intervention by injection, inh alation, or skin 
contact.
•A male family member or healthcare provider who has been exposed  to the study 
intervention by injection, inhalation, or skin contact then inse minates his female 
partner prior to or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hou rs of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The ini tial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).
•If EDP occurs in a participant or participant’s partner, the inv estigator must report 
this information to Pfizer Safety on the Vaccine SAE Reporting Fo rm and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. De tails of the 
pregnancy will be collected after the start of study interventi on and until Visit 2.
•If EDP occurs in the setting of environmental exposure, the inv estigator must report 
information to Pfizer Safety using the Vaccine SAE Reporting Form and EDP 
Supplemental Form. Since the exposure information does not pert ain to the 
participant enrolled in the study, the information is not recor ded on a CRF; however, 
a copy of the completed Vaccine SAE Reporting Form is maintained in the 
investigator site file.
Follow-up is conducted to obtain general information on the pre gnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer S afety of the outcome as a 
follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinicall y possible, the structural 
integrity of the terminated fetus should be assessed by gross v isual inspection (unless 
preprocedure test findings are conclusive for a congenital anom aly and the findings are 
reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome  of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abo rtion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live-born ba by, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigat or should follow the procedures 
for reporting SAEs. Additional information about pregnancy outc omes that are reported to 
Pfizer Safety as SAEs follows: PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 57•Spontaneous abortion including miscarriage and missed abortion sho uld be reported 
as an SAE;
•Neonatal deaths that occur within 1 month of birth should be rep orted, without regard 
to causality, as SAEs. In addition, infant deaths after 1 month s hould be reported as 
SAEs when the investigator assesses the infant death as related  or possibly related to 
exposure to the study intervention.
Additional information regarding the EDP may be requested by th e sponsor. Further 
follow-up of birth outcomes will be handled on a case-by-case b asis (eg, follow-up on 
preterm infants to identify developmental delays). In the case o f paternal exposure, the 
investigator will provide the participant with the Pregnant Par tner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Infor mation Form to provide to his 
partner.
8.4.5.2. Exposure During Breastfeeding
An EDB occurs if:
•A female participant is found to be breastfeeding while receivi ng or after 
discontinuing study intervention.
•A female nonparticipant is found to be breastfeeding while being  exposed or having 
been exposed to study intervention (ie, environmental exposure) . An example of 
environmental EDB is a female family member or healthcare provid er who reports 
that she is breastfeeding after having been exposed to the stud y intervention by
injection, inhalation, or skin contact.
The investigator must report EDB to Pfizer Safety within 24 hour s of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The info rmation must be reported 
using the Vaccine SAE Reporting Form. When EDB occurs in the setti ng of environmental 
exposure, the exposure information does not pertain to the part icipant enrolled in the study, 
so the information is not recorded on a CRF. However, a copy of  the completed Vaccine SAE
Reporting Form is maintained in the investigator site file.
An EDB report is not created when a Pfizer drug specifically app roved for use in 
breastfeeding women (eg, vitamins) is administered in accordanc e with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB.
8.4.5.3. Occupational Exposure
The investigator must report any instance of occupational expos ure to Pfizer Safety within 
24 hours of the investigator’s awareness using the Vaccine SAE Rep orting Form, regardless 
of whether there is an associated SAE. Since the information abo ut the occupational exposure
does not pertain to a participant enrolled in the study, the inf ormation is not recorded on a PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 58CRF; however, a copy of the completed Vaccine SAE Reporting Form must be maintained in 
the investigator site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease-Related Events and/or Disease-Related Outcomes No t Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Not applicable.
8.4.8.1. Lack of Efficacy
The investigator must report signs, symptoms, and/or clinical s equelae resulting from lack of 
efficacy. Lack of efficacy or failure of expected pharmacologic al action is reportable to Pfizer 
Safety only if associated with an SAE .
8.4.9. Medical Device Deficiencies
Medical devices being provided for use in this study are those l isted in Section 6.1.2 . In order 
to fulfill regulatory reporting obligations worldwide, the inves tigator is responsible for the 
detection and documentation of events meeting the definitions o f device deficiency that occur 
during the study with such devices.
The definition of a medical device deficiency can be found in Appendix 8.
Note: AEs and/or SAEs that are associated with a medical device  deficiency will follow the 
same processes as other AEs or SAEs, as outlined in Sections 8.4.1 through 8.4.4 and 
Appendix 3 of the protocol.
8.4.9.1. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be de tected, documented, and 
reported during all periods of the study in which the medical d evice is used.
Importantly, reportable device deficiencies are not limited to problems with the device itself 
but also include incorrect or improper use of the device and ev en intentional misuse, etc.
If the investigator learns of any device deficiency at any time a fter a participant has been 
discharged from the study, and such deficiency is considered rea sonably related to a medical 
device provided for the study, the investigator will promptly no tify the sponsor.
The method of documenting medical device deficiencies is provide d in Appendix 8 .PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 598.4.9.2. Follow-Up of Medical Device Deficiencies
Follow-up applies to all participants, including those who disco ntinue study intervention.
The investigator is responsible for ensuring that follow-up inc ludes any supplemental 
investigations as indicated to elucidate the nature and/or caus ality of the deficiency.
New or updated information will be recorded on a follow-up form with all changes signed 
and dated by the investigator.
8.4.9.3. Prompt Reporting of Device Deficiencies to the Sponsor
When a device deficiency occurs: 
1. The investigator notifies the sponsor by telephone or email with in 1 business day of 
determining that the incident meets the protocol definition of a medical device 
deficiency.
2. The device deficiency must be recorded on the Medical Device C omplaint form.
3. If an AE (either serious or nonserious) associated with the d evice deficiency occurs, 
then the AE must be entered into the AE section of the CRF.
4. If an SAE associated with the device deficiency is brought to  the attention of the 
investigator, the investigator must immediately notify Pfizer Sa fety of the SAE 
(seeSection 8.4.1.1 ). All relevant details related to the role of the device in th e event 
must be included in the Vaccine SAE Reporting Form as outlined in  Sections 8.4.1.1
and 8.4.1.2 .
The sponsor will be the contact for the receipt of device defici ency information.
8.4.9.4. Regulatory Reporting Requirements for Device Deficienci es
The investigator will promptly report all device deficiencies oc curring with any medical 
device provided for use in the study in order for the sponsor t o fulfill the legal responsibility 
to notify appropriate regulatory authorities and other entities  about certain safety information 
relating to medical devices being used in clinical studies.
The investigator, or responsible person according to local requir ements (eg, the head of the 
medical institution), will comply with the applicable local reg ulatory requirements relating to 
the reporting of device deficiencies to the IRB/EC.
8.4.10. Vaccination Errors
Vaccination errors may result from the administration or consum ption of the study 
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Vaccination errors are recorded and reported as follows:PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 60Recorded on the 
Vaccination Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the Vaccine 
SAE Reporting Form to 
Pfizer Safety Within 
24 Hours of Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the vaccination errorOnly if associated with an 
SAE
Vaccination errors include:
•Vaccination errors involving participant exposure to the study i ntervention;
•Potential vaccination errors or uses outside of what is foreseen  in the protocol that do 
or do not involve the study participant.
Other examples include, but are not limited to:
•The administration of expired study intervention;
•The administration of an incorrect study intervention;
•The administration of an incorrect dosage;
•The administration of study intervention that has undergone tem perature excursion 
from the specified storage range, unless it is determined by th e sponsor that the study 
intervention under question is acceptable for use.
Such vaccination errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE pa ge.
Whether or not the vaccination error is accompanied by an AE, as  determined by the 
investigator, the medication error is recorded on the medicatio n error page of the CRF and, if
applicable, any associated AE(s), serious and nonserious, are r ecorded on the AE page of the 
CRF.
In the event of a vaccination dosing error, the sponsor should be notified within 24 hours.
Vaccination errors should be reported to Pfizer Safety within 2 4 hours on a Vaccine SAE
Reporting Form only when associated with an SAE.
8.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 618.6. Genetics
8.6.1. Specified GeneticsSpecified genetic analyses are not evaluated in this study.
 
See Section 10.5 for information regarding genetic research. Details on processe s for 
collection and shipment of these samples will be provided separ ately.
8.6.2. Retained Research Samples for Genetics
Not applicable.
8.7. Biomarkers
Biomarkers are not evaluated in this study.
8.8. Immunogenicity Assessments
Immunogenicity assessments are described in Section 8.2 .
8.9. Health Economics
Health economics/medical resource utilization and health econom ics parameters are not 
evaluated in this study.
8.10. Study Procedures
Before enrollment and before any study-related procedures are p erformed, voluntary, written, 
study-specific informed consent will be obtained from the parti cipant. Each signature on the 
ICD must be personally dated by the signatory. The investigator  or his or her designee will 
also sign the ICD. A copy of the signed and dated ICD must be g iven to the participant. The 
source data must reflect that the informed consent was obtained  before participation in the 
study.
The timing of visit procedures (ie, prior to randomization and after randomization) must be 
maintained; however, there is flexibility in the order in which  the procedures can be 
conducted at each visit. The ICD must be signed prior to the st art of any study procedure.
8.10.1. Visit 1 – Study Intervention Administration – Day 1
Prior to randomization:
•Obtain a personally signed and dated ICD indicating that the pa rticipant has been 
informed of all pertinent aspects of the study before performin g any study-specific 
procedures.
•Assign a participant number via the IRT.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 62•Obtain and record the participant’s demographic information (in cluding date of birth, sex, 
race, and ethnicity). The complete date of birth (ie, DD-MMM-YY YY) will be collected 
to critically evaluate the immune response and safety profile b y age.
•Perform a clinical assessment. If the clinical assessment indic ates that a physical 
examination is necessary to comprehensively evaluate the partic ipant, perform a physical 
examination and record any findings in the source documents and , if significant, record 
such findings on the medical history CRF.
•Measure and record the participant’s oral temperature (°F/°C)
•Record nonstudy vaccinations given up to 28 days prior to study i ntervention 
administration, in source documents, if applicable (see Section 6.9 ).
•If applicable, instruct the participant to use appropriate cont raceptives until 28 days after 
administration of the last dose of study intervention and docum ent the conversation and 
the participant’s affirmation in the participant’s source docum ent (see Section 10.4 ).
•Perform urine pregnancy test for female participants of childbear ing potential
(seeSection 8.3.6 ).
•Ensure and document that all of the inclusion criteria and none  of the exclusion criteria 
are met.
•Assign a randomization number and a study intervention containe r number via the IRT. 
This must be the last step before proceeding. A site staff memb er will prepare the study 
intervention according to the IPM.
After randomization:
 
 
•Collect approximately 60 mL of blood prior to study intervention a dministration.
•Administer a single 0.25-mL or 0.5-mL injection of the assigned study intervention into 
the deltoid muscle of the preferably nondominant arm (see Section 6.1 ).PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 63After study intervention administration:
•Site staff will observe the participant for 30 minutes after ad ministration of study 
intervention for any reactions. Record any acute reactions (inc luding time of onset) in the 
participant’s source documents and on the AE page of the CRF, a nd on the Vaccine SAE 
Reporting Form, as applicable. Record concomitant medications us ed to treat SAEs.
•Record concomitant medications used to treat SAEs, if applicabl e.
•Record AEs and SAEs as described in Section 8.4 .
•Explain the e-diary technologies available for this study ( Section 8.3.1 ) and assist the 
participant in downloading the study application onto the parti cipant’s own device or 
issue a provisioned device, if required. Provide instructions o n the e-diary’s use and 
completion and ask the participant to complete the e-diary from  Day 1 through Day 7, 
with Day 1 being the day of study intervention administration.
•Issue the participant a measuring device to measure injection s ite reactions and a digital 
thermometer and provide instructions on their use.
•Ask the participant to contact the investigator site staff or i nvestigator as soon as possible 
during the 7-day postadministration period if the participant ha s redness and/or swelling 
at the injection site measuring >20 measuring device units (>10  cm) or severe injection 
site pain (prevents daily activity) to determine if an unschedu led visit is required (refer to 
Section 8.10.3 ).
•Ask the participant to contact the investigator site staff or i nvestigator as soon as possible 
if he or she experiences a fever ≥104°F (≥40.0°C) or any severe systemic event from 
Day 1 through Day 7 after study intervention administration (where  Day 1 is the day of
administration) to determine if an unscheduled visit is require d (see Section 8.10.3 ).
•Ask the participant to contact the site staff or investigator i mmediately if any significant 
illness or medical event (eg, emergency room visit or hospitali zation) occurs.
•Provide the participant with the participant contact card conta ining the study and 
investigator information (see Section 10.1.11 ).
•Remind the participant to use appropriate contraceptives until 28  days after study 
intervention administration, if applicable.
•Schedule an appointment for the participant to return for the n ext study visit.
•Remind the participant to bring the e-diary to the next visit.
•The investigator or an authorized designee completes the CRF an d the source documents 
and updates the study intervention accountability records.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 64•The investigator or appropriately qualified designee reviews th e e-diary data online at 
frequent intervals (daily is optimal) for the 7 days (Day 1 is the day of study intervention 
administration) following administration to evaluate participan t compliance and as part of 
the ongoing safety review.
8.10.2. Visit 2 – Follow-Up After Study Intervention Administrati on – 28 to 42 Days 
After Study Intervention Administration
•Ensure and document that the participant continues to be eligib le for the study 
(seeSection 7 for participant discontinuation/withdrawal).
•Record nonstudy vaccinations, if applicable, as described in Section 6.9 .
•Discuss contraceptive use since Visit 1 (see Section 10.4 ), if applicable, and record any 
contraceptive use in the source documents.
•Review the participant’s e-diary data. Collect stop dates of an y e-diary events (local 
reactions or systemic events) ongoing on the last day that the e-diary was completed and 
record stop dates in the CRF.
•Collect the participant’s e-diary or assist the participant in r emoving the study application 
from his or her own personal device.
•Determine if any AEs (including nonserious AEs and SAEs) have oc curred since the 
previous visit, follow up on any previously reported events to determine the outcome 
(ie, record stop dates or confirm if they are still continuing),  record such AEs as 
described in Section 8.4 , and record concomitant medications used to treat SAEs.
 
•The investigator or an authorized designee completes the CRF an d the source documents.
8.10.3. Unscheduled Visit for a Grade 3 Systemic Event or Suspec ted Grade 4 Reaction
If the participant reports redness or swelling at the injection  site measuring >20 measuring 
device units (>10.0 cm) or severe injection site pain ( Section 8.3.2.1 ), a temperature >40°CPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 65during the 7 days following study intervention administration at  Visit 1, or a severe systemic 
event ( Section 8.3.2.2 ) during the 7 days following study intervention administration at 
Visit 1, a telephone contact must occur as soon as possible betwe en the investigator or 
medically qualified designee and the participant to assess if a n unscheduled investigator site 
visit is required. A site visit should be scheduled as soon as possible to assess the extent of 
the injection site reaction unless any of the following is true :
•The participant is unable to attend the unscheduled visit.
•The reaction is no longer present at the time of the telephone contact.
•The participant recorded an incorrect value in the e-diary (con firmation of an e-diary 
data entry error).
•The PI or authorized designee determined it was not needed.
This telephone contact will be recorded in the participant’s so urce documentation and the 
CRF. If the participant is unable to attend the unscheduled vis it, or the PI or authorized 
designee determined it was not needed, any ongoing reactions mu st be assessed at the next 
study visit. During the unscheduled visit, the reactions should  be assessed by the investigator 
or a medically qualified member of the study staff, such as a s tudy physicia n or a study 
nurse, as applicable to the investigator’s local practice, who will:
•Measure oral temperature (°F/°C).
•Measure minimum and maximum diameters of redness (if present).
•Measure minimum and maximum diameters of swelling (if present).
•Assess injection site pain (if present) in accordance with the grades provided in 
Section 8.3.2.1 .
•Assess systemic events (if present) in accordance with the grad es provided in 
Section 8.3.2.2 .
•Assess for other findings associated with the reaction and reco rd on the AE page of 
the CRF, if appropriate.
The investigator or an authorized designee will complete the un scheduled visit assessment 
page of the CRF.
9. STATISTICAL CONSIDERATIONS
Methodology for summary and statistical analyses of the data co llected in this study is 
described here and further detailed in the SAP, which will be ma intained by the sponsor. The 
SAP may modify what is outlined in the protocol where appropria te; however, any major PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 66modifications of the primary endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.1. Statistical Hypothesis
There is no formal statistical hypothesis testing planned for t his study.
9.1.1. Estimands
The estimands corresponding to the primary and secondary object ives are described in the 
table in Section 3 . The estimands to evaluate the immunogenicity objectives will b e based on 
the evaluable immunogenicity population (see Section 9.2 for defi nition). The estimands 
estimate the study intervention effect in the hypothetical sett ing where participants follow the 
study schedules and protocol requirements as directed. Missing serology results will not be 
imputed. Immunogenicity results that are below the LLOQ will be  set to 0.5 × LLOQ in the 
analysis.
In the primary safety objective evaluations, missing e-diary da ta will not be imputed. A 
partial AE start date (eg, missing day, missing both month and day) will be imputed by 
assigning the earliest possible start date using all available information (eg, stop date of AE, 
vaccination date from the same participant) following the Pfize r standards for handling 
incomplete AE start date. An AE with a completely missing start  date is not allowed in the 
data collection. No other missing information will be imputed in  the safety analysis..
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are define d:
Participant Analysis Set Description
Enrolled All participants who sign the ICD.
Randomized All participants who are assigned a randomization num ber in 
the IRT system.
Evaluable immunogenicity All eligible randomized participants wh o receive the study 
intervention to which they are randomly assigned, have at least 1 valid immunogenicity result from the blood sample collected within an appropriate window 1 month after administration, and have no other major protocol deviations as determined by the clinician.
 
 
Safety All participants who receive the study intervention.PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 679.3. Statistical Analyses
The SAP will be developed and finalized before database lock for  any of the planned 
analyses in Section 9.4 . It will describe the analyses and procedures for accounting fo r 
missing, unused, and spurious data. This section is a summary of  the planned statistical 
analyses of the primary, secondary 
9.3.1. General Considerations
In general, the study data will be summarized by study intervent ion groups. CIs for all 
endpoints in the statistical analysis will be presented as 2-si ded at the 95% level.
 
 
Participants will be 
summarized according to the study intervention group to which t hey were randomized. 
Missing laboratory results will not be imputed.
The safety analyses are based on the safety population. Partici pants will be summarized 
according to the study interventions they received.
9.3.1.1. Analyses for Binary Data
Descriptive statistics for categorical variables (eg, proportio ns) are the percentage (%), the 
numerator (n) and denominator (N) used in the percentage calcul ation, and the 2-sided 95% 
CIs, where applicable.
The exact 95% CI for binary endpoints for each group will be co mputed using the 
F distribution (Clopper-Pearson).
9.3.1.2. Analyses for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
standard deviation, minimum, and maximum.
9.3.1.2.1. Geometric Means
The geometric mean for each group will be calculated as the mea n of the logarithmically 
transformed assay results and then exponentiating the mean. The 2-sided 95% CI will be 
obtained by exponentiating the CI for the mean of the logarithm ically transformed assay 
results based on Student’s t distribution.
 
 PPD
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 68 
 
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis
Endpoints and Estimands Statistics
•Percentage of participants with local reactions 
(redness, swelling, and pain at the injection site) within 7 days after study intervention administration in each group
•Percentage of participants with systemic events 
(fever, fatigue, headache, muscle pain, and joint pain) within 7 days after study intervention administration in each group•Descriptive summary statistics for 
participants with each local reaction/systemic event within 7 days after study intervention administration, by severity level
•Percentage of participants with AEs from 
study intervention administration through1 month after administration in each group•Descriptive summary statistics
•Percentage of participants with SAEs from 
study intervention administration through1 month after administration in each group•Descriptive summary statistics
9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis
Endpoints and Estimands Statistics
•  OPA GMT 1 month after study 
intervention administration •GMT and 2-sided 95% CI
 
 
 
 
 PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 69 
.
9.4. Interim Analyses
No interim analysis will be conducted for this study. As this is an open-label study, the 
sponsor may conduct unblinded reviews of the data during the co urse of the study for the 
purpose of safety assessment and/or for supporting clinical devel opment.
9.4.1. Analysis Timing
Statistical analyses will be carried out as specified below:
•An analysis will be conducted when safety data through approxim ately 1 month after 
study intervention administration are available.
•Immunogenicity data of OPA and IgG results through Visit 2 (1 mo nth after study 
intervention administration) may be analyzed, when available, f or 1 or more 
immunogenicity endpoints  
.
•A final analysis of safety, including complete OPA and IgG result s available after the 
completion of the study, will be performed.  
This is an open-label Phase 1 exploratory study. Immunogenicity  data reviews by the sponsor 
may be conducted at any time the data are available to aid in d ecision-making for the sponsor 
programs.
Certain analyses may be combined if the data become available a round the same time. 
Additional analyses may be conducted or combined if required for  regulatory purposes or for 
further clinical evaluation of the study intervention.
9.5. Sample Size Determination
The sample size of this study is not driven by any formal hypot hesis test. It is determined 
primarily based on the consideration of providing pioneer infor mation on the immune 
responses induced by the candidates and the corresponding safety  profiles in order to 
support a decision for further clinical development.
The primary safety objective includes the endpoints for AEs, lo cal reactions, and systemic 
events. Table 5 shows the binomial probability of detecting at least 1 AE. The n umber of 
participants in each study group is 45, which provides a >90% c hance of observing at least 
1 event in a group, assuming a true event rate of at least 5%.PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 70Table 5. Probability of Detecting at Least 1 Adverse Event in a S tudy Group
True Rate of AEs Probability of Observing at Least 1 AE
2.0% 59.7%
3.0% 74.6%
4.0% 84.1%
5.0% 90.1%
6.0% 93.8%PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 7110. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Consi derations
10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol an d with the following:
•Consensus ethical principles derived from international guideli nes, including the 
Declaration of Helsinki and CIOMS International Ethical Guideli nes;
•Applicable ICH GCP guidelines;
•Applicable laws and regulations, including applicable privacy l aws.
The protocol, protocol amendments, ICD, SRSD(s), and other rele vant documents 
(eg, advertisements) must be reviewed and approved by the sponso r, submitted to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC bef ore the study is initiated.
Any amendments to the protocol will require IRB/EC approval bef ore implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
Protocols and any substantial amendments to the protocol will r equire health authority 
approval prior to initiation except for changes necessary to eli minate an immediate hazard to 
study participants.
The investigator will be responsible for the following:
•Providing written summaries of the status of the study to the I RB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;
•Notifying the IRB/EC of SAEs or other significant safety findin gs as required by 
IRB/EC procedures;
•Providing oversight of the conduct of the study at the site and  adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, Europea n regulation 
536/2014 for clinical studies, European Medical Device Regulati on 2017/745 for 
clinical device research, and all other applicable local regula tions.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the  Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, cli nical hold) by an applicable 
regulatory authority in any area of the world, or if the invest igator is aware of any new 
information that might influence the evaluation of the benefits  and risks of the study 
intervention, Pfizer s hould be informed immediately.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 72In addition, the investigator will inform Pfizer immediately of  any urgent safety measures 
taken by the investigator to protect the study participants aga inst any immediate hazard, and 
of any serious breaches of this protocol or of the ICH GCP guid elines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor wit h sufficient, accurate financial 
information as requested to allow the sponsor to submit complet e and accurate financial 
certification or disclosure statements to the appropriate regul atory authorities. Investigators 
are responsible for providing information on financial interest s during the course of the study 
and for 1 year after completion of the study.
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will expla in the nature of the study, 
including the risks and benefits, to the participant and answer a ll questions regarding the 
study. The participant should be given sufficient time and oppor tunity to ask questions and to 
decide whether or not to participate in the trial.
Participants must be informed that their participation is volun tary. Participants will be 
required to sign a statement of informed consent that meets the  requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy and data protection r equirements, where 
applicable, and the IRB/EC or study center.
The investigator must ensure that each participant is fully info rmed about the nature and 
objectives of the study, the sharing of data related to the stud y, and possible risks associated 
with participation, including the risks associated with the pro cessing of the participant’s 
personal data.
The participant must be informed that their personal study-relate d data will be used by the 
sponsor in accordance with local data protection law. The level  of disclosure must also be 
explained to the participant
The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appoin ted by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory a uthorities.
The investigator further must ensure that each study participan t is fully informed about their
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written inform ed consent was obtained 
before the participant was enrolled in the study and the date o n which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 73Participants must be reconsented to the most current version of the IRB/EC-approved ICD(s) 
during their participation in the study as required per local re gulations.
A copy of the ICD(s) must be provided to the participant.10.1.4. Data Protection
All parties will comply with all applicable laws, including law s regarding the implementation 
of organizational and technical measures to ensure protection o f participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will impleme nt appropriate technical and 
organizational measures to ensure that the personal data can be  recovered in the event of 
disaster. In the event of a potential personal data breach, the  study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.
To protect the rights and freedoms of participants with regard t o the processing of personal 
data, participants will be assigned a single, participant-speci fic numerical code. Any 
participant records or data sets that are transferred to the spo nsor will contain the numerical 
code; participant names will not be transferred. All other iden tifiable data transferred to the 
sponsor will be identified by this single, participant-specific  code. The study site will 
maintain a confidential list of participants who participated i n the study, linking each 
participant’s numerical code to their actual identity and medical  record ID. In case of data 
transfer, the sponsor will protect the confidentiality of parti cipants’ personal data consistent 
with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and st ore study-related data are 
secured by technical and organizational security measures desig ned to protect such data 
against accidental or unlawful loss, alteration, or unauthorize d disclosure or access.
The sponsor maintains SOPs on how to respond in the event of una uthorized access, use, or 
disclosure of sponsor information or systems.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee This study will not use an EDMC.
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical st udy results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.go v), the EudraCT/CTIS, and/or 
www.pfizer.com, and other public registries and websites in acc ordance with applicable local 
laws/regulations. In addition, Pfizer reports study results out side of the requirements of local 
laws/regulations pursuant to its SOPs.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 74In all cases, study results are reported by Pfizer in an object ive, accurate, balanced, and 
complete manner and are reported regardless of the outcome of t he study or th e country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov f or Pfizer-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or  efficacy of a product, 
regardless of the geographical location in which the study is c onducted. These results are 
submitted for posting in accordance with the format and timelin es set forth by US law.
EudraCT/CTIS
Pfizer posts clinical trial results on EudraCT/CTIS for Pfizer-s ponsored interventional studies 
in accordance with the format and timelines set forth by EU req uirements.
www.pfizer.com
Pfizer posts CSR synopses and plain-language study results summ aries on www.pfizer.com 
for Pfizer-sponsored interventional studies at the same time the  corresponding study results 
are posted to www.clinicaltrials.gov. CSR synopses will have pers onally identifiable 
information anonymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publi sh clinical documents included 
in marketing applications. Clinical documents include summary d ocuments and CSRs 
including the protocol and protocol amendments, sample CRFs, an d SAPs. Clinical 
documents will have personally identifiable information anonymi zed.
Data sharing
Pfizer provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of 
the disease, target, or compound class. Pfizer will make data fr om these trials available 
24 months after study completion. Participant-level data will be  anonymized in accordance 
with applicable privacy laws and regulations. CSRs will have per sonally identifiable 
information anonymized.
Data requests are considered from qualified researchers with the  appropriate competencies to 
perform the proposed analyses. Research teams must include a bio statistician. Data will not 
be provided to applicants with significant conflicts of interes t, including individuals 
requesting access for commercial/competitive or legal purposes.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 7510.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, labo ratory data). The investigator is 
responsible for verifying that data entries are accurate and co rrect by physically or 
electronically signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Comp letion Requirements 
document.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password protected or secur ed in a locked room to 
prevent access by unauthorized third parties.
QTLs are predefined parameters that are monitored during the stud y. Important deviations 
from the QTLs and any remedial actions taken will be summarized  in the CSR.
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to sour ce data documents. This 
verification may also occur after study completion. It is impor tant that the investigator(s) and 
their relevant personnel are available during the monitoring vi sits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of  study-critical data items and 
processes (eg, risk-based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk-based monitoring), met hods, responsibilities, and 
requirements, including handling of noncompliance issues and mo nitoring techniques 
(central, virtual, or on-site monitoring), are provided in the da ta management plan and 
monitoring plan maintained and utilized by the sponsor or design ee.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the  conduct of this study must 
be retained by the investigator for 15 years after study complet ion unless local regulations or 
institutional policies require a longer retention period. No re cords may be destroyed during 
the retention period without the written approval of the sponso r. No records may be 
transferred to another location or party without written notifi cation to the sponsor. The 
investigator must ensure that the records continue to be stored  securely for as l ong as they are 
maintained.
When participant data are to be deleted, the investigator will e nsure that all copies of such 
data are promptly and irrevocably deleted from all systems.
The investigator(s) will notify the sponsor or its agents immedia tely of any regulatory 
inspection notification in relation to the study. Furthermore, t he investigator will cooperate 
with the sponsor or its agents to prepare the investigator site  for the inspection and will allow PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 76the sponsor or its agent, whenever feasible, to be present duri ng the inspection. The 
investigator site and investigator will promptly resolve any di screpancies that are identified 
between the study data and the participant’s medical records. T he investigator will promptly 
provide copies of the inspection findings to the sponsor or its  agent. Before response 
submission to the regulatory authorities, the investigator will  provide the sponsor or its 
agents with an opportunity to review and comment on responses t o any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from s ource documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or tra nsfer records, depending on 
the study. Also, current medical records must be available.
In this study, the CRF will serve as the source document. A doc ument must be available at 
the investigative site that identifies those data that will be r ecorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes source data and its origin can b e found in the Source 
Document Locator, which is maintained by the sponsor.
Description of the use of the computerized system is documented in the data management 
plan, which is maintained by the sponsor
The investigator must maintain accurate documentation (source d ata) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that d ata entered into the CRF 
by authorized site personnel are accurate, complete, and verifi able from source documents; 
that the safety and rights of participants are being protected;  and that the study is being 
conducted in accordance with the currently approved protocol an d any other study 
agreements, ICH GCP guidelines, and all applicable regulatory re quirements.
10.1.9. Study and Site Start and Closure
The study start date is the date on which the clinical study wi ll be open for recruitment of 
participants.
The first act of recruitment is the date of the first participa nt’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site  or terminate the study at any 
time for any reason at the sole discretion of the sponsor, incl uding (but not limited to) 
regulatory authority decision, change in opinion of the IRB/EC,  or change in benefit-risk PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 77assessment. Study sites will be closed upon study completion. A study site is considered 
closed when all required documents and study supplies have been  collected and a study-site 
closure visit has been performed.
The investigator may initiate study-site closure at any time upo n notification to the sponsor 
or designee/CRO if requested to do so by the responsible IRB/EC or if such termination is 
required to protect the health of study participants.
Reasons for the early closure of a study site by the sponsor ma y include but are not limited 
to:
•Failure of the investigator to comply with the protocol, the req uirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, o r the ICH GCP 
guidelines;
•Inadequate recruitment of participants by the investigator;
•Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponso r shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and an y CRO(s) used in the study of 
the reason for termination or suspension, as specified by the a pplicable regulatory 
requirements. The investigator shall promptly inform the partic ipant and should assure 
appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study ag reement. If there is any conflict 
between the contract and this protocol, the contract will contro l as to termination rights.
10.1.10. Publication Policy
For multicenter trials, the primary publication will be a joint  publication developed by the 
investigator and Pfizer reporting the primary endpoint(s) of the  study covering all study sites. 
The investigator agrees to refer to the primary publication in any subsequent publications. 
Pfizer will not provide any financial compensation for the inve stigator’s participation in the 
preparation of the primary congress abstract, poster, presentat ion, or primary manuscript for 
the study.
Investigators are free to publish individual center results tha t they deem to be clinically 
meaningful after publication of the overall results of the study  or 12 months after primary 
completion date or study completion at all sites, whichever occ urs first, subject to the other 
requirements described in this section.
The investigator will provide Pfizer an opportunity to review a ny proposed publication or 
any other type of disclosure of the study results (collectively , “publication”) before it is 
submitted or otherwise disclosed and will submit all publication s to Pfizer 30 days before 
submission. If any patent action is required to protect intellect ual property rights, the 
investigator agrees to delay the disclosure for a period not to exceed an additional 60 days PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 78upon request from Pfizer. This allows Pfizer to protect propriet ary information and to provide 
comments, and the investigator will, on request, remove any pre viously undisclosed 
confidential information before disclosure, except for any stud y-intervention or Pfizer-related 
information necessary for the appropriate scientific presentati on or understanding of the 
study results. For joint publications, should there be disagree ment regarding interpretation 
and/or presentation of specific analysis results, resolution of , and responsibility for, such 
disagreements will be the collective responsibility of all auth ors of the publication.
For all publications relating to the study, the investigator an d Pfizer will comply with 
recognized ethical standards concerning publications and author ship, including those 
established by the International Committee of Medical Journal E ditors. The investigator will 
disclose any relationship with Pfizer and any relevant potentia l conflicts of interest, including 
any financial or personal relationship with Pfizer, in any publi cations. All authors will have 
access to the relevant statistical tables, figures, and reports  (in their original format) required 
to develop the publication.
10.1.11. Sponsor’s Medically Qualified Individual 
The contact information for the sponsor’s MQI for the study is d ocumented in the study 
contact list located in the supporting study documentation/stud y portal or other electronic 
system.
To facilitate access to their investigator and the sponsor’s MQ I for study-related medical 
questions or problems from nonstudy healthcare professionals, pa rticipants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identif ication number, (c) site 
emergency phone number active 24 hours/day, 7 days per week, an d (d) Pfizer Call Center 
number.
The ECC is intended to augment, not replace, the established co mmunication pathways 
between the participant and their investigator and site staff, and between the investigator and 
sponsor study team. The ECC is only to be used by healthcare pr ofessionals not involved in 
the research study, as a means of reaching the investigator or site staff related to the care of a 
participant. The Pfizer Call Center number is to be used when th e investigator and site staff 
are unavailable. The Pfizer Call Center number is not for use by  the participant directly; if a 
participant calls that number directly, they will be directed ba ck to the investigator site.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 7910.2. Appendix 2: Clinical Laboratory Tests
Unscheduled clinical laboratory measurements may be obtained at  any time during the study 
to assess any perceived safety issues. The investigator must re view the laboratory report, 
document this review, and record any clinically relevant change s occurring during the study 
in the AE section of the CRF.
Pregnancy test (β-hCG): Local urine testing will be standard fo r the protocol unless serum 
testing is required by local regulation or IRB/EC for participa nts who are WOCBP.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 8010.3. Appendix 3: Adverse Events: Definitions and Procedures for  Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition
•An AE is any untoward medical occurrence in a patient or clinic al study participant, 
temporally associated with the use of study intervention, wheth er or not considered 
related to the study intervention.
•Note: An AE can therefore be any unfavorable and unintended sig n (including an 
abnormal laboratory finding), symptom, or disease (new or exace rbated) temporally 
associated with the use of study intervention.
Events Meeting the AE Definition
•Any abnormal laboratory test results (hematology, clinical chem istry, or urinalysis) 
or other safety assessments (eg, ECG, radiological scans, vital  sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnorma l laboratory test 
results that meet any of the conditions below must be recorded as an AE:
•Is associated with accompanying symptoms.
•Requires additional diagnostic testing or medical/surgical inte rvention.
•Leads to a change in study dosing (outside of any protocol-spec ified dose 
adjustments) or discontinuation from the study, significant add itional 
concomitant drug treatment, or other therapy.
•Exacerbation of a chronic or intermittent preexisting condition , including an 
increase in either frequency and/or intensity of the condition.
•New condition detected or diagnosed after study intervention ad ministration, even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdo se of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE or SAE unless it is an intentional overdose taken with possib le 
suicidal/self-harming intent. Such overdoses should be reported  regardless of 
sequelae.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 81Events NOT Meeting the AE Definition
•Any clinically significant abnormal laboratory findings or othe r abnormal safety 
assessments that are associated with the underlying disease, un less judged by the 
investigator to be more severe than expected for the participan t’s condition.
•The disease/disorder being studied or expected progression, sig ns, or symptoms of 
the disease/disorder being studied, unless more severe than exp ected for the 
participant’s condition.
•Medical or surgical procedure (eg, endoscopy, appendectomy): th e condition that 
leads to the procedure is the AE.
•Situations in which an untoward medical occurrence did not occu r (social and/or 
convenience admission to a hospital).
•Anticipated day-to-day fluctuations of preexisting disease(s) o r condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at an y dose, meets one or 
more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers  to an event in which the 
participant was at risk of death at the time of the event. It do es not refer to an event that
hypothetically might have caused death if it were more severe.
c. Requires inpatient hospitalization or prolongation of existin g hospitalization
In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emerge ncy ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalizat ion are AEs. If a 
complication prolongs hospitalization or fulfills any other ser ious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE should be considered serious.
Hospitalization for elective treatment of a preexisting conditi on that did not worsen 
from baseline is not considered an AE.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 82d. Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’ s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relat ively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle), that may interfere wi th or prevent 
everyday life functions but do not constitute a substantial dis ruption.
e. Is a congenital anomaly/birth defect
f. Is a suspected transmission via a Pfizer product of an infect ious agent, pathogenic 
or nonpathogenic
The event may be suspected from clinical symptoms or laboratory  findings indicating an 
infection in a participant exposed to a Pfizer product. The term s “suspected 
transmission” and “transmission” are considered synonymous. The se cases are 
considered unexpected and handled as serious expedited cases by  pharmacovigilance 
personnel. Such cases are also considered for reporting as prod uct defects, if 
appropriate.
g. Other situations:
•Medical or scientific judgment should be exercised by the inves tigator in deciding 
whether SAE reporting is appropriate in other situations, such a s significant medical 
events that may jeopardize the participant or may require medic al or surgical 
intervention to prevent one of the other outcomes listed in the  above definition.
These events should usually be considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, bloo d dyscrasias or
convulsions that do not result in hospitalization, or developmen t of drug dependency 
or drug abuse.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 8310.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs Durin g the Active 
Collection Period 
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on  the CRF and for 
reporting SAEs on the Vaccine SAE Reporting Form to Pfizer Safety t hroughout the active 
collection period. These requirements are delineated for 3 type s of events: (1) SAEs; 
(2) nonserious AEs; and (3) exposure to the study intervention un der study during 
pregnancy or breastfeeding, and occupational exposure.
It should be noted that the Vaccine SAE Reporting Form for report ing of SAE information 
is not the same as the AE page of the CRF. When the same data a re collected, the forms 
must be completed in a consistent manner. AEs should be recorded  using concise medical 
terminology and the same AE term should be used on both the CRF  and the Vaccine SAE
Reporting Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine
SAE Reporting Form to Pfizer Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeeding All AEs or SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an AE or SAE are not captured in the CRFAll instances of EDP are 
reported (whether or not there is an associated SAE)*
All instances of EDB are 
reported (whether or not there is an associated SAE)**
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB)None. Exposure to a study 
nonparticipant is not collected on the CRFThe exposure (whether or 
not there is an associated AE or SAE) must be reported***
*EDP (with or without an associated AE or SAE): any pregnancy inform ation is reported to Pfizer 
Safety using the Vaccine SAE Reporting Form and EDP Supplemental Form; if the EDP is associated 
with an SAE, then the SAE is reported to Pfizer Safety using th e Vaccine SAE Reporting Form.
** EDB is reported to Pfizer Safety using the Vaccine SAE Reporting Form , which would also include 
details of any SAE that might be associated with the EDB.*** Environmental or occupational exposure: AEs or SAEs associated with occupational exposure are 
reported to Pfizer Safety using the Vaccine SAE Reporting Form.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 84•When an AE or SAE occurs, it is the responsibility of the invest igator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostic 
reports) related to the event.
•The investigator will then record all relevant AE or SAE informa tion in the CRF.
•It is notacceptable for the investigator to send photocopies of the part icipant’s 
medical records to Pfizer Safety in lieu of completion of the V accine SAE Reporting
Form/AE or SAE CRF page.
•There may be instances when copies of medical records for certa in cases are 
requested by Pfizer Safety. In this case, all participant identi fiers, with the exception 
of the participant number, will be redacted on the copies of the  medical records 
before submission to Pfizer Safety.
•The investigator will attempt to establish a diagnosis of the e vent based on signs, 
symptoms, and/or other clinical information. Whenever possible,  the diagnosis (not 
the individual signs/symptoms) will be documented as the AE or S AE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:
•Mild: A type of AE that is usually transient and may require onl y minimal treatment 
or therapeutic intervention. The event does not generally inter fere with usual ADL.
•Moderate: A type of AE that is usually alleviated with addition al specific 
therapeutic intervention. The event interferes with usual ADL, ca using discomfort,
but poses no significant or permanent risk of harm to the resea rch participant.
•Severe: A type of AE that interrupts usual ADL, or significantly  affects clinical 
status, or may require intensive therapeutic intervention.
GRADE If required on the AE page of the CRF, the investigator w ill use the adjectives 
MILD, MODERATE, SEVERE to describe the maximum intensity of the  
AE. For purposes of consistency, these intensity grades are defi ned as 
follows:
1 MILD Does not interfere with participant’s usual 
function.
2 MODERATE Interferes to some extent with participant’s usual 
function.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 853 SEVERE Interferes significantly with participant’s usual 
function.
An event is defined as “serious” when it meets at least 1 of th e predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
•The investigator is obligated to assess the relationship betwee n study intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
•A “reasonable possibility” of a relationship conveys that there  are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
•Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event  to study intervention 
administration, will be considered and investigated.
•The investigator will also consult the IB and/or product inform ation, for marketed 
products, in their assessment.
•For each AE or SAE, the investigator must document in the medical notes that they 
have reviewed the AE or SAE and have provided an assessment of cau sality.
•There may be situations in which an SAE has occurred and the in vestigator has 
minimal information to include in the initial report to the spo nsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data  to the sponsor.
•The investigator may change their opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated ca usality 
assessment.
•The causality assessment is one of the criteria used when deter mining regulatory 
reporting requirements.
•If the investigator does not know whether or not the study inte rvention caused the 
event, then the event will be handled as “related to study inte rvention” for reporting 
purposes, as defined by the sponsor. In addition, if the invest igator determines that 
an SAE is associated with study procedures, the investigator mu st record this 
causal relationship in the source documents and CRF, and report  such an 
assessment in the dedicated section of the Vaccine SAE Reporting Form and in 
accordance with the SAE reporting requirements.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 86Follow-Up of AEs and SAEs
•The investigator is obligated to perform or arrange for the con duct of supplemental 
measurements and/or evaluations, as medically indicated or as r equested by the 
sponsor, to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or inves tigations, 
histopathological examinations, or consultation with other heal thcare providers.
•If a participant dies during participation in the study or duri ng a recognized 
follow-up period, the investigator will provide Pfizer Safety w ith a copy of any 
postmortem findings, including histopathology.
•New or updated information will be recorded in the originally s ubmitted documents.
•The investigator will submit any updated SAE data to the sponso r within 24 hours of 
receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic DCT
•The primary mechanism for reporting an SAE to Pfizer Safety will  be the electronic 
DCT.
•If the electronic system is unavailable, then the site will use  the paper SAE DCT
(see next section) to report the event within 24 hours.
•The site will enter the SAE data into the electronic DCT (eg, eSA E or PSSA) or 
paper form (as applicable) as soon as the data become available.
•After the study is completed at a given site, the electronic DC T will be taken off-line 
to prevent the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participa nt or receives updated 
data on a previously reported SAE after the electronic DCT has b een taken off-line, 
then the site can report this information on a paper SAE form ( see next section) or to 
Pfizer Safety by telephone.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 87SAE Reporting to Pfizer Safety via the Vaccine SAE Reporting Fo rm
•Facsimile transmission of the Vaccine SAE Reporting Form is the  preferred method 
to transmit this information to Pfizer Safety.
•In circumstances when the facsimile is not working, an alternat ive method should be 
used, eg, secured (Transport Layer Security) or password-protec ted email. If none of 
these methods can be used, notification by telephone is accepta ble with a copy of the 
Vaccine SAE Reporting Form sent by overnight mail or courier se rvice.
•Initial notification via telephone does not replace the need fo r the investigator to 
complete and sign the Vaccine SAE Reporting Form pages within t he designated 
reporting time frames.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 8810.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study intervention, which 
corresponds to the time needed to eliminate reproductive safety  risk of the study 
intervention(s)
•Refrain from donating sperm.
PLUS either :
•Be abstinent from heterosexual intercourse as their preferred a nd usual lifestyle 
(abstinent on a long-term and persistent basis) and agree to re main abstinent.
OR
•Must agree to use contraception/barrier as detailed below:
•Agree to use a male condom when having sexual intercourse with a  WOCBP who 
is not currently pregnant.
•In addition to male condom use, a highly effective method of con traception may be 
considered in WOCBP partners of male participants (refer to the l ist of highly 
effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of inclusion criterion 1 (Age and S ex; Section 5.1 ) and specify the 
reproductive requirements for including female participants. Re fer to Section 10.4.4 for a 
complete list of contraceptive methods permitted in the study.
A female participant is eligible to participate if she is not pr egnant or breastfeeding and at 
least 1 of the following conditions applies:
•Is not a WOCBP (see definitions below in Section 10.4.3 ).
•OR
•Is a WOCBP and agrees to use an acceptable contraceptive method d uring the 
intervention period (for a minimum of 28 days after the last dose  of study 
intervention). The investigator should evaluate the effectivene ss of the contraceptive 
method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman w ith an early undetected 
pregnancy.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 8910.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until beco ming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athle tes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, addit ional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1. Premenarchal.2. Premenopausal female with 1 of the following:
•Documented hysterectomy;
•Documented bilateral salpingectomy;
•Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cau se other than the above
(eg, mullerian agenesis, androgen insensitivity), investigator d iscretion should be applied to 
determining study entry.
Note: Documentation for any of the above categories can come fr om the site personnel’s 
review of the participant’s medical records, medical examinatio n, or medical history 
interview. The method of documentation should be recorded in th e participant’s medical 
record for the study.
3. Postmenopausal female:
•A postmenopausal state is defined as no menses for 12 months wit hout an alternative 
medical cause. In addition:
•A high FSH level in the postmenopausal range must be used to co nfirm a 
postmenopausal state in women under 60 years of age and not using  hormonal 
contraception or HRT.
•A female on HRT and whose menopausal status is in doubt will be  required to use 
one of the highly effective nonestrogen hormonal contraception m ethods if she
wishes to continue her HRT during the study. Otherwise, she must di scontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 9010.4.4. Contraception Methods
Contraceptive use by men or women should be consistent with loca l availability/regulations 
regarding the use of contraceptive methods for those participat ing in clinical trials.
The following contraceptive methods are appropriate for this st udy:
Highly Effective Methods That Have Low User Dependency
1. Implantable progestogen-only hormone contraception associated  with inhibition of 
ovulation.
2. Intrauterine device.3. Intrauterine hormone-releasing system.4. Bilateral tubal occlusion.5. Vasectomized partner:
•Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highly effective method o f contraception 
should be used. The spermatogenesis cycle is approximately 90 da ys.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contr aception associated 
with inhibition of ovulation:
•Oral;
•Intravaginal;
•Transdermal.
7. Progestogen-only hormone contraception associated with inhibi tion of ovulation:
•Oral;
•Injectable.
Sexual Abstinence
8. Sexual abstinence is considered a highly effective method onl y if defined as 
refraining from heterosexual intercourse during the entire peri od of risk associated 
with the study intervention. The reliability of sexual abstinen ce needs to be evaluated PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 91in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.
Other Effective Methods
9. Progestogen-only oral hormonal contraception where inhibition  of ovulation is not the 
primary mode of action.
10. Male or female condom, with or without spermicide.11. Cervical cap, diaphragm, or sponge with spermicide.12. A combination of male condom with either cervical cap, diaph ragm, or sponge with 
spermicide (double-barrier methods).PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 9210.5. Appendix 5: Genetics
Use/Analysis of DNA
 
 
 
•The results of genetic analyses may be reported in the CSR or i n a separate study 
summary, or may be used for internal decision making without bei ng included in a 
study report.
•The sponsor will store the DNA and/or RNA samples in a secure st orage space with 
adequate measures to protect confidentiality.
•The samples will be retained as indicated:
•Samples for specified genetic analysis (see Section 8.6.1 ) will be stored for up to 
15 years or other period as per local requirements.
•Samples for genetic research will be labeled with a code. The ke y between the code 
and the participant’s personally identifying information (eg, na me, address) will be 
held securely at the study site.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 9310.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as d etermined by elevations in 
transaminases) are termed “tolerators,” while those who show tr ansient liver injury but adapt 
are termed “adaptors.” In some participants, transaminase eleva tions are a harbinger of a 
more serious potential outcome. These participants fail to adap t and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × U LN should be monitored 
more frequently to determine if they are “adaptors” or are “sus ceptible.”
LFTs are not required as a routine safety monitoring procedure in this study. However, should 
an investigator deem it necessary to assess LFTs because a part icipant presents with clinical 
signs/symptoms, such LFT results should be managed and followed  as described below.
In the majority of DILI cases, elevations in AST and/or ALT pre cede T bili elevations 
(>2 × ULN) by several days or weeks. The increase in T bili typi cally occurs while AST/ALT 
is/are still elevated above 3 × ULN ( ie, AST/ALT a nd T bili valu es will be elevated within 
the same laboratory sample). In rare instances, by the time T bil i elevations are detected, 
AST/ALT values might have decreased. This occurrence is still r egarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR ALT in addition  to T bili that meet the 
criteria outlined below are considered potential DILI (assessed  per Hy’s law criteria) cases
and should always be considered important medical events, even before all other possible 
causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI c ase depends on the 
participant’s individual baseline values and underlying conditi ons. Participants who present 
with the following laboratory abnormalities should be evaluated  further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
•Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bil i value 
≥2 × ULN with no evidence of hemolysis and an alkaline phosphatas e value 
<2 × ULN or not available.
•For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned  above, as needed, 
depending on which values are above the ULN at baseline:
•Preexisting AST or ALT baseline values above the normal range: A ST or ALT 
values ≥2 times the baseline values AND ≥3 × ULN; or ≥8 × ULN (whic hever is 
smaller).PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 94•Preexisting values of T bili above the normal range: T bili level  increased from 
baseline value by an amount of ≥1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).
Rises in AST/ALT and T bili sepa rated by more than a few weeks s hould be assessed 
individually based on clinical judgment; any case where uncertai nty remains as to whether it 
represents a potential Hy’s law case should be reviewed with th e sponsor.
The participant should return to the investigator site and be ev aluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal result s. This evaluation should 
include laboratory tests, detailed history, and physical assess ment.
In addition to repeating measurements of AST and ALT and T bili f or suspected Hy’s law
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consid eration should also be given 
to drawing a separate tube of clotted blood and an anticoagulate d tube of blood for further 
testing, as needed, for further contemporaneous analyses at the  time of the recognized initial 
abnormalities to determine etiology. A detailed history, includ ing relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itsel f or as a coformulated 
product in prescription or over-the-counter medications), recre ational drug, or supplement 
(herbal) use and consumption, family history, sexual history, t ravel history, history of contact 
with a jaundiced person, surgery, blood transfusion, history of  liver or allergic disease, and 
potential occupational exposure to chemicals, should be collect ed. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laborat ory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DI LI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnor malities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 9510.7. Appendix 7: Kidney Safety Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and D etection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseli ne and postbaseline serum 
creatinine (Scr measurement to eGFR [Scr-based eGFR] or [eCrCl]).  Baseline and 
postbaseline Scys makes it feasible to distinguish AKI from oth er causes of Scr increase. If 
Scr increase is confirmed after baseline, then reflex measureme nt of Scys is indicated to 
estimate the combined Scr-Scys eGFR calculation (for adults only ).
Regardless of whether kidney function monitoring tests are requ ired as a routine safety 
monitoring procedure in the study, if the investigator or spons or deems it necessary to further 
assess kidney safety and quantify kidney function, then these t est results should be managed 
and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
10.7.2.1. Adults (18 Years and Above)—2021 CKD-EPI Equations
2021 CKD-EPI
Scr OnlyScr
(mg/dL)Scys
(mg/L) Recommended eGFR Equation
Female if ≤0.7 N/A eGFR = 143 × (Scr/0.7)-0.241  ×  (0.9938)Age
Female if >0.7 N/A eGFR = 143 × (Scr/0.7)-1.200  ×  (0.9938)Age
Male if ≤0.9 N/A eGFR = 142 × (Scr/0.9)-0.302  ×  (0.9938)Age
Male if >0.9 N/A eGFR = 142 × (Scr/0.9)-1.200  ×  (0.9938)Age
2021 CKD-EPI Scr-Scys CombinedScr
(mg/dL)Scys
(mg/L) Recommended eGFR Equation
Female if ≤0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.219  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Female if ≤0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.219  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Female if >0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.544  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Female if >0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.544  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Male if ≤0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.144  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Male if ≤0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.144  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Male if >0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.544  ʹ(Scys/0.8)-0.323  ʹ(0.9961)Age
Male if >0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.544  ʹ(Scys/0.8)-0.778  ʹ(0.9961)Age
Note: The table source is Inker LA, et al. N Engl J Med. 2021;3 85(18):1737-49.
10.7.3. Adverse Event Grading for Kidney Safety Laboratory Abnorm alities
AE grading for decline in kidney function (ie, eGFR or eCrCl) wi ll be according to KDIGO
criteria.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 9610.8. Appendix 8: AEs, ADEs, SAEs, SADEs, USADEs, and Device Defic iencies:
Definitions and Procedures for Recording, Evaluating, Follow-Up,  and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in  accordance with ISO 14155
and the European MDR 2017/745 for clinical device research (if applicable).
Both the investigator and the sponsor will comply with all loca l reporting requirements for 
medical devices.
The detection and documentation procedures described in this pr otocol apply to all sponsor 
medical devices provided for use in the study (see Section 6.1.2 for the list of sponsor 
medical devices).
10.8.1. Definition of AE and ADE
AE and ADE Definition
•An AE is defined in Appendix 3 (Section 10.3.1 ).
•An ADE is defined as an AE related to the use of an investigatio nal medical device. 
This definition includes any AEs resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, o r operation, or any 
malfunction of the investigational medical device as well as an y event resulting 
from use error or from intentional misuse of the investigationa l medical device.
10.8.2. Definition of SAE, SADE, and USADE
SAE Definition
•An SAE is defined in Appendix 3 (Section 10.3.2 ).
SADE Definition
•An SADE is defined as an ADE that has resulted in any of the con sequences 
characteristic of an SAE.
•Any device deficiency that might have led to an SAE if appropri ate action had not 
been taken, intervention had not occurred, or circumstances had  been less fortunate.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 97USADE Definition
•A USADE (also identified as UADE in US Regulations 21 CFR 813.3) is a SADE
that by its nature, incidence, severity, or outcome has not been  identified in the 
current version of the risk analysis management file.
10.8.3. Definition of Device Deficiency
Device Deficiency Definition
•A device deficiency is an inadequacy of a medical device with r espect to its identity, 
quality, durability, reliability, safety, or performance. Device  deficiencies include 
malfunctions, use errors, and inadequate information supplied by  the manufacturer.
10.8.4. Recording/Reporting and Follow-Up of Medical Device Defici encies
Device Deficiency Recording
•When a device deficiency occurs, it is the responsibility of th e investigator to review 
all documentation (eg, hospital progress notes, laboratory repo rts, and diagnostic 
reports) related to the event.
•The investigator will then record all relevant device deficiency  information in the 
participant’s medical records, in accordance with the investiga tor’s normal clinical 
practice, and will also capture the required information on the Medical Device 
Complaint form.
•It is notacceptable for the investigator to send photocopies of the part icipant’s 
medical records to Pfizer Safety in lieu of following the report ing process described 
in the Medical Device Complaint form.
•There may be instances when copies of medical records for certa in cases are 
requested by Pfizer Safety. In this case, all participant ident ifiers, with the exception 
of the participant number, will be redacted on the copies of th e medical records 
before submission to Pfizer Safety.
•If the investigator determines that the medical device deficien cy may have injured 
the participant (ie, the medical device deficiency is associate d with an AE or SAE), 
then the investigator will attempt to establish a diagnosis of the event based on 
signs, symptoms, and/or other clinical information. Whenever po ssible, the 
diagnosis will be documented in the participant’s medical recor d and recorded as the PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 98AE or SAE rather than the individual signs/symptoms. Requirement s for recording 
and reporting an AE or SAE are provided in Appendix 3 (Section 10.3.3 ).
•For device deficiencies, it is very important that the investig ator describes any 
corrective or remedial actions taken to prevent recurrence of t he incident.
•A remedial action is any action other than routine maintenance o r servicing of a 
medical device where such action is necessary to prevent recurr ence of a device 
deficiency. This includes any amendment to the device design to  prevent 
recurrence.
Assessment of Causality Occurring in Conjunction With a Medical Device Deficiency
•If an AE or SAE has occurred in conjunction with a medical devi ce deficiency, the 
investigator must assess the relationship between each occurren ce of the AE or SAE 
and the medical device deficiency. The investigator will use cl inical judgment to 
determine the relationship.
•A “reasonable possibility” of a relationship conveys that there  are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
•Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event  to study intervention 
administration will be considered and investigated.
•The investigator will also consult the IB in their assessment.
•For each device deficiency, the investigator must document in the medical notes 
that they have reviewed the device deficiency and have provided a n assessment of 
causality.
•There may be situations in which an SAE has occurred and the in vestigator has 
minimal information to include in the initial report to the spo nsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to the sponsor.
•The investigator may change their opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated ca usality 
assessment.
•The causality assessment is one of the criteria used when deter mining regulatory 
reporting requirements.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 99Follow-Up of Medical Device Deficiency
•The investigator is obligated to perform or arrange for the con duct of supplemental 
measurements and/or evaluations, as medically indicated or as re quested by the 
sponsor to elucidate the nature and/or causality of the device d eficiency as fully as 
possible. This may include additional laboratory tests or inves tigations, 
histopathological examinations, or consultation with other heal thcare providers.
•New or updated information regarding the nature of the device d eficiency will be 
recorded in the originally completed Medical Device Complaint fo rm.
•New or updated information regarding any SAE that was potential ly associated with 
the medical device deficiency will be submitted to Pfizer Safety  on the Vaccine SAE 
Reporting Form within 24 hours of receipt of the information, a ccording to the 
requirements provided in Appendix 3 .
10.8.5. Reporting of SAEs
Reporting of an SAE to Pfizer Safety must be performed accordin g to the processes 
described in Appendix 3 (Section 10.3.4 ).
10.8.6. Reporting of SADEs
SADE Reporting to Pfizer Safety
Note: There are additional reporting obligations for medical de vice deficiencies that are 
potentially related to SAEs (ie, an SADE) that must fulfill the leg al responsibility to notify 
appropriate regulatory authorities and other entities about cer tain safety information relating 
to medical devices being used in clinical studies.
•Any device deficiency that is associated with an SAE must be rep orted to the 
sponsor within 24 hours after the investigator determines that the event meets the 
definition of a device deficiency.
•The sponsor shall review all device deficiencies and determine and document in 
writing whether they could have led to an SAE. These shall be r eported to the 
regulatory authorities and IRBs/ECs as required by national regu lations.PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 10010.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may be used in th e protocol.
Abbreviation Term
7vPnC 7-valent pneumococcal conjugate vaccine
9vPnC 9-valent pneumococcal conjugate vaccine
13vPnC 13-valent pneumococcal conjugate vaccine
20vPnC 20-valent pneumococcal conjugate vaccine
ADE adverse device effect
ADL activity/activities of daily living
AE adverse event
AKI acute kidney injury
AlPO 4 aluminum phosphate
ALT alanine aminotransferase
AST aspartate aminotransferase
AxMP auxiliary medicinal product
BCR B-cell receptor
b-hCG b-human chorionic gonadotropin
CBER Center for Biologics Evaluation and Research
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Science s
CK creatine kinase
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
CONSORT Consolidated Standards of Reporting Trials
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 2019
CRF case re port form
CRO contract research organization
CSR clinical study report
CTIS Clinical Trial Information System
DCT data collection tool
DILI drug-induced liver injury
DNA deoxyribonucleic acid
DU dispensable unit
EC ethics committee
ECC emergency contact card
ECG electrocardiogram
eCrCl estimated creatinine clearance
eCRF electronic case report formPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 101Abbreviation Term
EDB exposure during breastfeeding
e-diary electronic diary
EDMC External Data Monitoring Committee
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
eSAE electronic serious adverse event
EU European Union
EudraCT European Union Drug Regulating Authorities Clinical Tria ls 
(European Clinical Trials Database)
FDA (United States) Food and Drug Administration
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GMC geometric mean concentration
GMFR geometric mean fold rise
GMT geometric mean titer
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical Require ments 
for Pharmaceuticals for Human Use
ID identification
IgG immunoglobulin G
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IPAL Investigational Product Accountability Log
IPD invasive pneumococcal disease
IPM investigational product manual
IRB institutional review board
IRT interactive response technology
ISO International Organization for Standardization
IWR interactive Web- based response
KDIGO Kidney Disease: Improving Global Outcomes
LFT liver function test
LLOQ lower limit of quantitation
MDR medical device regulation
MHCII major histocompatibility complex class II
PPDPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 102Abbreviation Term
MQI medically qualified individual
N/A not applicable
NIMP noninvestigational medicinal product
NIP national immunization program
OM otitis media
OPA o psono phagocytic activit y
PCV15 15-valent pneumococcal conjugate vaccine
PFS prefilled syringe
PI principal investi gator
PPE personal protective equipment
PPSV23 23-valent pneumococcal polysaccharide vaccine
PSSA Pfizer's Serious Adverse Event Submission Assistant
PT prothrombin time
QTL quality tolerance limit
RAC reductive amination chemistry
RNA ribonucleic acid
SADE serious adverse device effect
SAE serious adverse event
SAP statistical analysis plan
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2
Scr serum creatinine
Scys serum cystatin C
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safety document
SUSAR suspected unexpected serious adverse reaction
TBD to be determined
T bili total bilirubin
TCR T-cell receptor
UADE unanticipated adverse device effect
ULN upper limit of normal
US United States
USADE unanticipated serious adverse device effect
USPI United States prescribing information
VE vaccine efficacy
WOCBP woman/women of childbearing potentialPPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 10311. REFERENCES
1Theilacker C, Fletcher MA, Jodar L, et al. PCV13 vaccination of  adults against 
pneumococcal disease: what we have learned from the Community-A cquired 
Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms . 2022;10(1):127.
 
 
 
 
 
 
 
 
 
 
7Lode H, Schmoele-Thoma B, Gruber W, et al. Dose-ranging study o f a single injection 
of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy  subjects aged 70 years 
or older. Vaccine. 2011;29(31):4940-6.
 
9Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 di fferent formulations of 
15-valent pneumococcal conjugate vaccine (PCV15) in healthy inf ants. Hum Vaccin 
Immunother. 2019;15(3):549-59. 
10Wantuch PL, Sun L, LoPilato RK, et al. Isolation and characteri zation of new human 
carrier peptides from two important vaccine immunogens. Vaccine . 2020;38(10):2315-
25.                                                PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 10411Savulescu C, Krizova P, Slotved HC, et al. Effectiveness of 13- valent pneumococcal 
conjugate vaccine on invasive pneumococcal disease in the Europ ean Union: results of 
SpIDnet multicentre study. Poster presented at ESPID 36th Annua l Meeting; 28 May–02 
June 2018; Malmö, Sweden.
12Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of th e seven-valent and 
thirteen-valent pneumococcal conjugate vaccines in England: the  indirect cohort design, 
2006-2018. Vaccine. 2019;37(32):4491-8. 
13Dagan R, Van Der Beek BA, Ben-Shimol S, et al. Effectiveness of  the 7- and 13-valent 
pneumococcal conjugate vaccines against vaccine-serotype otitis  media. Clin Infect Dis. 
2021;73(4):650-8. 
14Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analys is of serotype-
specific vaccine efficacy of 13-valent pneumococcal conjugate v accine against clinical 
community acquired pneumonia from a randomized clinical trial i n the Netherlands. 
Vaccine. 2019;37(30):4147-54. 
15Warren JL, Weinberger DM. Estimating serotype-specific efficacy  of pneumococcal 
conjugate vaccines using hierarchical models. Epidemiology. 202 0;31(2):259-62. 
16Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non- vaccine serotypes 
causing invasive pneumococcal disease in England and Wales, 200 0-17: a prospective 
national observational cohort study. Lancet Infect Dis. 2018;18 (4):441-51. 
17van der Linden M, Imöhl M, Perniciaro S. Limited indirect effec ts of an infant 
pneumococcal vaccination program in an aging population. PLoS O ne. 
2019;14(8):e0220453. 
18Grant LR, Slack MPE, Theilacker C, et al. Invasive pneumococcal  disease due to 
serotypes in pneumococcal vaccines in older adults of high-incom e countries. Poster 
presentation at the 12th International Symposium on Pneumococci  and Pneumococcal 
Diseases (ISPPD-12); 19-23 June 2022; Toronto, Canada. Available u pon request.
 
 
 
 
 PPD
Protocol C4801001
Final Protocol, 26 May 2022
PFIZER CONFIDENTIAL
Page 105 
 
 
 
 
24Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemic al function from a 
few good reactions. Angew Chem Int Ed Engl. 2001;40(11):2004-21.  
25Takayama Y, Kusamori K, Nishikawa M. Click chemistry as a tool for cell engineering 
and drug delivery. Molecules. 2019;24(1):172. 
26US Food and Drug Administration. Guidance for industry: toxicit y grading scale for 
healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluation and Research; Se ptember 2007.PPD
'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH		 


 

   
'RFXPHQW 7LWOH  	  ! "#$# % # % &#'% %
 (%)   '*  %) ( '# +'*% ('#%    #%) '#% 	 %'* , ) ( *
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
PPD